Document:

Exhibit 10.26

 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is
not material and the registrant customarily and actually treats as private and confidential.

 

LOAN
AND SECURITY AGREEMENT

THIS LOAN AND SECURITY AGREEMENT
is made and dated as of September 14, 2020 and is entered into by and among CENTURY THERAPEUTICS, LLC, a Delaware limited liability
company, and each of its Subsidiaries (hereinafter collectively referred to as the “Borrower”), the several banks and
other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as the “Lenders”)
and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and
the Lenders (in such capacity, the “Agent”).

 

RECITALS

 

A.                
Borrower has requested the Lenders make available to Borrower a loan in an aggregate principal amount of up to Thirty Million
Dollars ($30,000,000) (the “Term Loan”); and

 

B.                
The Lenders are willing to make the Term Loan on the terms and conditions set forth in this Agreement.

 

AGREEMENT

 

NOW, THEREFORE, Borrower, Agent and the Lenders agree
as follows:

 

SECTION
1. DEFINITIONS AND RULES OF CONSTRUCTION

 

1.1             
Unless otherwise defined herein, the following capitalized terms shall have the following meanings:

 

“Account Control Agreement(s)”
means any agreement entered into by and among the Agent, Borrower and a third party bank or other institution (including a Securities
Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which perfects Agent’s
first priority security interest in the subject account or accounts.

 

“ACH
Authorization” means the ACH Debit Authorization Agreement in substantially the form of Exhibit H, which account numbers
shall be redacted for security purposes if and when filed publicly by the Borrower.

 

“Acquisition” means
any transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in (a) the acquisition
of all or substantially all of the assets of a Person, or of any business, line of business or division or other unit of operation
of a Person, (b) the acquisition of fifty percent (50%) or more of the Equity Interests of any Person, whether or not involving
a merger, consolidation or similar transaction with such other Person, or otherwise causing any Person to become a Subsidiary of
Borrower, or (c) the acquisition of, or the right to use, develop or sell (in each case, including through licensing (other than
 “off-the-shelf” licenses)), any product, product line or intellectual property of or from any other Person.

 

“Advance(s)” means a Term Loan Advance.

 

“Advance Date” means the funding date of
any Advance.

     

    	 

    

 

“Advance Request” means
a request for an Advance submitted by Borrower to Agent in substantially the form of Exhibit A, which account numbers shall be
redacted for security purposes if and when filed publicly by the Borrower.

 

“Affiliate”
means (a) any Person that directly or indirectly controls, is controlled by, or is under common control with the Person in
question, (b) any Person directly or indirectly owning, controlling or holding with power to vote twenty percent (20%) or
more of the outstanding voting securities of another Person, (c) any Person twenty percent (20%) or more of whose outstanding
voting securities are directly or indirectly owned, controlled or held by another Person with power to vote such securities,
or (d) any Person related by blood or marriage to any Person described in subsection (a), (b) or (c) of this paragraph. As
used in the definition of “Affiliate,” (i) the term “control” means the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through
ownership of voting securities, by contract or otherwise; and (ii) neither Bayer, Versant Ventures Capital VI, L.P., nor
Fujifilm Cellular Dynamics, Inc., nor their respective affiliates, shall be considered “Affiliates” of Borrower
or its Subsidiaries.

“Agreement”
means this Loan and Security Agreement, as amended from time to time. “All Source Proceeds” means unrestricted
(including, not subject to any redemption, clawback, escrow or similar encumbrance or restriction) net cash proceeds from one
or more bona fide equity financings and/or upfront proceeds from strategic partnerships and/or new business development
transactions permitted under this Agreement, in each case after the Closing Date and subject to verification by Agent
(including supporting documentation reasonably requested by Agent); provided that any remaining portion of the Bayer First
Tranche received by Borrower after the Closing Date will count as All Source Proceeds.

 

“Amortization Date”
means November 1, 2022; provided however, if the Interest Only Extension Conditions are satisfied, then May 1, 2023.

 

“Anti-Corruption Laws”
means all laws, rules, and regulations of any jurisdiction applicable to Borrower or any of its controlled Affiliates from time
to time concerning or relating to bribery or corruption, including without limitation the United States Foreign Corrupt Practices
Act of 1977, as amended, the UK Bribery Act 2010 and other similar legislation in any other jurisdictions.

 

“Anti-Terrorism Laws”
means any laws, rules, regulations or orders relating to terrorism or money laundering, including without limitation Executive
Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act,
and the laws administered by OFAC.

 

“Bayer” means Bayer HealthCare LLC, a Delaware
limited liability company.

 

“Bayer First Tranche”
means the “First Tranche Commitment Amount” as defined in the Commitment Agreement; and means an amount equal to One
Hundred Forty-Five Million Dollars ($145,000,000) (of which $75,000,000 has funded prior to the Closing Date and, for the avoidance
of doubt, does not count as All Source Proceeds).

 

“Blocked
Person” means any Person: (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No.
13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is
otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from
dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires
to commit or 

 

 

    	2

    	 

    

  

supports “terrorism” as defined in Executive Order No. 13224, or (e) a Person that is named a
 “specially designated national” or “blocked person” on the most current list published by OFAC or
other similar list.

 

“Borrower Products” means
all products, software, service offerings, technical data or technology currently being designed, manufactured or sold by Borrower
or which Borrower intends to sell, license, or distribute in the future including any products or service offerings under development,
collectively, together with all products, software, service offerings, technical data or technology that have been sold, licensed
or distributed by Borrower since its formation.

 

“Borrower’s Books”
means Borrower’s or any of its Subsidiaries’ books and records including ledgers, federal, state, local and foreign
tax returns, records regarding Borrower’s or its Subsidiaries’ assets or liabilities, the Collateral, business operations
or financial condition, and all computer programs or storage or any equipment containing such information.

 

“Business Day” means any
day other than Saturday, Sunday and any other day on which banking institutions in the State of California are closed for business.

 

“Cash” means all cash, cash equivalents
and liquid funds.

 

“Century” means Century Therapeutics, Inc.,
a Delaware corporation.

 

“Century
Canada” means Century Therapeutics Canada ULC, an unlimited liability company organized under the laws of British Columbia,
Canada, and a wholly-owned Subsidiary of Borrower.

 

“Change in Control”
means any reorganization, recapitalization, consolidation or merger (or similar transaction or series of related transactions)
of Borrower, sale or exchange of outstanding Equity Interests (or similar transaction or series of related transactions; other
than a sale of Borrower’s Equity Interests in a bona fide venture financing (or series of financings) in the ordinary course
of business) of Borrower in which the holders of Borrower’s outstanding Equity Interests immediately before consummation
of such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related
transactions, retain Equity Interests representing more than fifty percent (50%) of the voting power of the surviving entity of
such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned
by such parent), in each case without regard to whether Borrower is the surviving entity; or any other transaction pursuant to
which Bayer (together with its Affiliates) owns at least eighty percent (80%) of Borrower’s Equity Interests on a Fully Diluted
Basis (as defined in the Operating Agreement) after giving effect to such transaction or series of related transactions.

 

“Closing Date” means the date of this
Agreement.

 

“Code” means the Internal Revenue Code of
1986, as amended.

 

“Commitment Agreement”
means that certain Commitment Agreement dated as of June 21, 2019, by and among Borrower, Century Therapeutics, Inc. and Bayer;
as amended by the First Amendment, and in the form delivered to Agent prior to the Closing Date, as amended from time to time;
provided that such amendments are provided to Agent in accordance with Section 7.1(g).

 

“Contingent Obligation”
means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i)
any Indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly
guaranteed, endorsed, 

 

    	3

    	 

    

  

co-made or discounted or sold with recourse by that
Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn
letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations
arising under any interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement,
or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates
or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection
or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed
to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation
is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such
Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under
the guarantee or other support arrangement.

 

“Copyright License” means
any written agreement granting any right to use any Copyright or Copyright registration, now owned or hereafter acquired by Borrower
or in which Borrower now holds or hereafter acquires any interest.

 

“Copyrights”
means all copyrights, whether registered or unregistered, and any applications in connection therewith, held pursuant to the laws
of the United States of America, any State thereof, or of any other country.

 

“Default” means any
event, circumstance or condition that has occurred or exists, that would, with the passage of time or the requirement that notice
be given or both, become an Event of Default.

 

“Deposit Accounts”
means any “deposit accounts,” as such term is defined in the UCC, and includes any checking account, savings account,
or certificate of deposit.

 

“Domestic Subsidiary”
means any Subsidiary organized under the laws of the United States of America, any State thereof, the District of Columbia, or
any other jurisdiction within the United States of America.

 

“Due Diligence Fee”
means Thirty Thousand Dollars ($30,000), which fee has been paid to the Lenders prior to the Closing Date, and shall be deemed
fully earned on such date regardless of the early termination of this Agreement.

 

“Empirica Promissory
Note” means the unsecured Promissory Note dated June 9, 2020, by and among Century Canada and Empirica Therapeutics, Inc.;
in the form delivered to Agent prior to the Closing Date; and with a principal amount equal to Two Million Canadian Dollars (CAN
$2,000,000).

 

“Equity Interests”
means, with respect to any Person, the capital stock, partnership or limited liability company interest, or other equity securities
or equity ownership interests of such Person.

 

“ERISA” means the
Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.

 

“Excluded Accounts”
means (a) Deposit Accounts exclusively used for payroll, payroll taxes, and other employee wage and benefit payments to or for
the benefit of Borrower’s employees holding an aggregate amount across all such accounts of not more than amounts needed
for the then-next two (2) payroll cycles and (b) deposit, securities, commodity or similar accounts with financial

 

    	4

    	 

    

  

 institutions within the United States, so long
as no more than $50,000 in the aggregate is maintained in such accounts at any time.

 

“FDA”
means the U.S. Food and Drug Administration or any successor thereto. “Foreign Subsidiary” means any Subsidiary
other than a Domestic Subsidiary. “GAAP” means generally accepted accounting principles in the United States of
America, as in effect from time to time.

 

“Governmental Authority”
is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory
body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions
of or pertaining to government, any securities exchange and any self-regulatory organization.

 

“IND” means an Investigational
New Drug Application submitted to the FDA pursuant to 21 C.F.R. § 312 (or its successor regulation) requesting authorization
to initiate clinical trials in human subjects.

 

“Indebtedness” means
indebtedness of any kind, including (a) all indebtedness for borrowed money or the deferred purchase price of property or services
(excluding trade credit entered into in the ordinary course of business due within ninety (90) days), including reimbursement and
other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures
or similar instruments, (c) all capital lease obligations, (d) equity securities of any Person subject to repurchase or redemption
other than at the sole option of such Person, (e) “earnouts”, purchase price adjustments, profit sharing arrangements,
deferred purchase money amounts and similar payment obligations or continuing obligations of any nature arising out of purchase
and sale contracts, (f) obligations arising under bonus, deferred compensation, incentive compensation or similar arrangements
(other than those arising in the ordinary course of business or otherwise reflected in Board-approved plans disclosed to Agent
from time to time), (g) non-contingent obligations to reimburse any bank or Person in respect of amounts paid under a letter of
credit, banker’s acceptance or similar instrument, and (h) all Contingent Obligations.

 

“Initial Facility Charge”
means Two Hundred Thousand Dollars ($200,000), which is payable to the Lenders in accordance with Section 4.1(f).

 

“Insolvency Proceeding”
means any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law,
including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking
reorganization, arrangement, or other similar relief.

 

“Intellectual Property”
means all of Borrower’s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; mask works; Borrower’s
applications therefor and reissues, extensions, or renewals thereof; and Borrower’s goodwill associated with any of the foregoing,
together with Borrower’s rights to sue for past, present and future infringement of Intellectual Property and the goodwill
associated therewith.

 

“Interest Only Extension
Conditions” shall mean satisfaction of each of the following events: (a) no Default or Event of Default shall have occurred
and be continuing; and (b) Borrower’s achievement of Performance Milestone III on or prior to August 31, 2022.

 

    	5

    	 

    

  

“Investment”
means (a) any beneficial ownership (including stock, partnership, limited liability company interests, or other securities) of
or in any Person, (b) any loan, advance or capital contribution to any Person or (c) any Acquisition.

 

“IRS” means the United States Internal Revenue
Service.

 

“Joinder Agreements” means
for each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto as Exhibit F.

 

“License” means
any Copyright License, Patent License, Trademark License or other license of rights or interests.

 

“Lien” means any mortgage,
deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind,
whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title
retention agreement, and any lease in the nature of a security interest.

 

“Loan” means the Advances made under this
Agreement.

 

“Loan Documents” means
this Agreement, the promissory notes (if any), the ACH Authorization, the Account Control Agreements, the Joinder Agreements, all
UCC Financing Statements, the Warrant, the Pledge Agreement, and any other documents executed in connection with the Secured Obligations
or the transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated.

 

“Material Adverse Effect”
means a material adverse effect upon: (i) the business, operations, properties, assets or financial condition of Borrower and its
Subsidiaries taken as a whole; or

(ii) 
the ability of Borrower to perform or pay the Secured Obligations in accordance with the terms of the Loan Documents, or
the ability of Agent or the Lenders to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii)
the Collateral or Agent’s Liens on the Collateral or the priority of such Liens.

 

“Maximum Term Loan Amount” means Thirty
Million and No/100 Dollars

($30,000,000).

 

“Non-Disclosure
Agreement” means that certain Non-Disclosure Agreement by and between Hercules Capital, Inc. and Borrower dated as of May
3, 2020.

 

“OFAC” is the
U.S. Department of Treasury Office of Foreign Assets Control.

 

“OFAC Lists” are,
collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224,
66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any
of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.

 

“Operating Agreement”
means the Amended and Restated Limited Liability Company Agreement of Borrower dated as of June 21, 2019 as amended by that certain
First Amendment dated as of the Effective Date in the form provided to Agent as of the Closing Date, as the same may be amended
from time to time; provided that such amendments are provided to Agent in accordance with Section 7.1(g).

 

    	6

    	 

    

  

“Option Agreement”
means that certain Option Agreement dated as of June 21, 2019, by and among Borrower, Century Therapeutics, Inc., and Bayer; in
the form delivered to Agent prior to the Closing Date, as the same may be amended from time to time; provided that such amendments
are provided to Agent in accordance with Section 7.1(g).

 

“Patent License” means
any written agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application
is pending, in which agreement Borrower now holds or hereafter acquires any interest.

 

“Patents”
means all letters patent of, or rights corresponding thereto, in the United States of America or in any other country, all registrations
and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States of America
or any other country.

 

“Performance Milestone I”
means (a) no Default or Event of Default shall have occurred and be continuing and (b) Borrower has (i) demonstrated pre-clinical
proof-of-concept for all allogeneic iNK cell therapy; (ii) received at least Sixty-Five Million Dollars ($65,000,000) in All Source
Proceeds; provided that Agent may, in its sole discretion, reduce such amount of minimum All Source Proceeds consistent with adjustments
to Borrower’s projections and the anticipated timing of various events/initiatives, as reviewed and approved by Agent; and
(iii) demonstrated pre-clinical proof-of- concept for an allogeneic iT cell therapy product, in each case of the foregoing clauses
(i) through (iii), subject to verification by Agent in its reasonable discretion (including supporting documentation reasonably
requested by Agent).

 

“Performance Milestone
II” means (a) no Default or Event of Default shall have occurred and be continuing and (b) Borrower has (i) achieved Performance
Milestone I and (ii) received at least One Hundred Twenty Million Dollars ($120,000,000) in cumulative All Source Proceeds (including
amounts raised or received in connection with satisfaction of Performance Milestone I), which must include the completion of a
bona fide equity financing, which financing shall include an institutional investor reasonably acceptable to Agent which was not
an investor in Borrower as of the Closing Date, subject to verification by Agent (including supporting documentation reasonably
requested by Agent); provided that Agent may, in its sole discretion, reduce such amount of minimum All Source Proceeds consistent
with adjustments to Borrower’s projections and the anticipated timing of various events/initiatives, as reviewed and approved
by Agent.

 

“Performance Milestone
III” means (a) no Default or Event of Default shall have occurred and be continuing and (b) Borrower has (i) achieved Performance
Milestone II and (ii) in Agent’s reasonable discretion, demonstrated satisfactory progress towards the filing of an IND of
an allogeneic cell therapy product.

 

“Permitted
Acquisition” means any Acquisition, in each case located entirely within the United States of America, which is conducted
in accordance with the following requirements:

 

(a)               
of a business or Person or product engaged in a line of business related to that of the Borrower or its Subsidiaries;

 

(b)              
if such Acquisition is structured as a stock acquisition, then the Person so acquired shall either (i) become a wholly-owned
Subsidiary of Borrower or of a Subsidiary and the Borrower shall comply, or cause such Subsidiary to comply, with Section 7.13
hereof or (ii) such Person shall be merged with and into Borrower (with the Borrower being the surviving entity);

 

    	7

    	 

    

  

(c)               
if such Acquisition is structured as the acquisition or in-licensing of assets, such assets shall be acquired by Borrower
or a Subsidiary of Borrower that has executed a Joinder Agreement, shall be related to or complementary to Borrower’s core
technology or required for specific product candidate constructs (i.e. cell therapy design, delivery technology, target-specific
IP, etc.), and shall be free and clear of Liens other than Permitted Liens;

 

(d)              
the Borrower shall have delivered to the Lenders not less than fifteen (15) nor more than forty five (45) days prior to
the date of such Acquisition, notice of such Acquisition together with pro forma projected financial information, copies of all
material documents relating to such acquisition, and historical financial statements for such acquired entity, division or line
of business, in each case in form and substance satisfactory to the Lenders and demonstrating compliance with the covenants set
forth in Section 7.20 hereof on a pro forma basis as if the Acquisition occurred on the first day of the most recent measurement
period;

 

(e)              
both immediately before and after such Acquisition no Default or Event of Default shall have occurred and be continuing;
and

 

(f)             
the sum of the purchase price of all such proposed new Acquisitions, in the aggregate, computed on the basis of total acquisition
consideration paid or incurred, or to be paid or incurred, by Borrower with respect thereto, including any contingent or deferred
acquisition consideration due and/or payable during the term of this Agreement, and including the amount of Permitted Indebtedness
assumed or to which such assets, businesses or business or ownership interest or shares, or any Person so acquired, is subject,
shall not be greater than (i) $4,000,000 for any single acquisition or group of related acquisitions or (ii) $6,000,000 for all
such acquisitions during the term of this Agreement.

 

“Permitted Indebtedness” means:

 

(i)          
Indebtedness of Borrower in favor of the Lenders or Agent arising under this Agreement or any other Loan Document;

 

		(ii)	Indebtedness existing on the Closing Date which is disclosed in Schedule 1A;

 

(iii)      
Indebtedness of up to $1,500,000 outstanding at any time secured by a Lien described in clause (vii) of the defined term
 “Permitted Liens,” provided such Indebtedness does not exceed the cost of the Equipment financed with such Indebtedness;

 

(iv)      
Indebtedness to trade creditors incurred in the ordinary course of business, including such Indebtedness incurred in the
ordinary course of business with corporate credit cards in an amount not to exceed $500,000 at any time outstanding;

 

		(v)	Indebtedness that also constitutes a Permitted Investment;

 

		(vi)	Subordinated Indebtedness;

 

(vii)    
reimbursement obligations in connection with letters of credit that are secured by Cash and issued on behalf of the Borrower
or a Subsidiary thereof in an amount not to exceed

$250,000 at any time outstanding,

 

(viii)  
Indebtedness arising from honoring by a bank or other financial institution of a check, draft or similar instrument drawn
against insufficient funds in the ordinary course of 

 

    	8

    	 

    

  

business, provided that such Indebtedness is extinguished
within ten (10) days of Borrower or its Subsidiaries obtaining notice or knowledge of its incurrence;

 

(ix)      
Indebtedness of Borrower and its Subsidiaries incurred in connection with financing of insurance premiums in the ordinary
course of business;

 

(x)        
Indebtedness incurred in connection with netting services incurred in the ordinary course of business;

 

(xi)      
Indebtedness arising out of currency or commodity swap agreements, interest rate cap agreements, interest rate collar agreements
or other similar agreements entered into in the ordinary course of business and not for speculation

 

(xii)    
other unsecured Indebtedness in an amount not to exceed $250,000 at any time outstanding,

 

(xiii)  
intercompany Indebtedness as long as either (A) each of the Subsidiary obligor and the Subsidiary obligee under such Indebtedness
is a Subsidiary that has executed a Joinder Agreement; and

 

(xiv)  
extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not
increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be.

 

“Permitted Investment” means:

 

		(i)	Investments existing on the Closing Date which are disclosed in Schedule 1B;

 

(ii)        
(a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or
any State thereof maturing within one year from the date of acquisition thereof currently having a rating of at least A-2 or P-2
from either Standard & Poor’s Corporation or Moody’s Investors Services, (b) commercial paper maturing no more
than one year from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either Standard &
Poor’s Corporation or Moody’s Investors Service, (c) certificates of deposit issued by any bank with assets of at least
$500,000,000 maturing no more than one year from the date of investment therein, (d) money market accounts and (e) any other investments
permitted under the Investment Policy Statement of the Borrower dated as of November 12, 2018, as updated from time to time to
the extent a copy of such updates have been provided to, and reviewed by, Agent;

 

(iii)      
repurchases of stock from former employees, directors, or consultants of Century, Borrower or its Subsidiaries under the
terms of applicable repurchase agreements at the original issuance price of such securities in an aggregate amount not to exceed
$250,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or could exist after giving effect to
the repurchases;

 

		(iv)	Investments accepted in connection with Permitted Transfers;

 

(v)        
Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers
and in settlement of delinquent obligations 

 

    	9

    	 

    

  

of, and other disputes with, customers or suppliers
arising in the ordinary course of Borrower’s business;

 

(vi)      
Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers
who are not Affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments
of Borrower in any Subsidiary;

 

(vii)    
Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis of cash proceeds
to employees, officers, managers or directors relating to the purchase of capital stock of Century, Borrower or its Subsidiaries
pursuant to employee stock purchase plans or other similar agreements approved by Century’s, Borrower’s or a Subsidiary’s
Board of Directors or similar governing body;

 

(viii)  
Investments consisting of (i) travel advances and employee relocation loans in the ordinary course of business, and (ii)
loans to employees, officers, managers or directors relating to the purchase of equity securities of Century, Borrower or its Subsidiaries
pursuant to employee stock purchase plans or agreements approved by Century’s, Borrower’s or its Subsidiary’s
Board of Directors or similar governing body; not to exceed $250,000 in the aggregate for (i) and (ii) during the term of this
Agreement;

 

(ix)      
Investments in newly-formed Subsidiaries, provided that each such Subsidiary enters into a Joinder Agreement promptly after
its formation by Borrower and execute such other documents as shall be reasonably requested by Agent;

 

(x)        
Investments in (i) Foreign Subsidiaries approved in advance in writing by Agent; and (ii) Century Canada, not to exceed
$200,000 in the aggregate in any fiscal year, provided however up to CAN $2,000,000 may be invested in Century Canada solely for
the purposes of paying the amounts due under the Empirica Promissory Note as such amounts come due in accordance with the terms
of the Empirica Promissory Note in effect as of the Closing Date;

 

(xi)      
joint ventures or strategic alliances in the ordinary course of Borrower’s business consisting of the nonexclusive
licensing of technology, the development of technology or the providing of technical support, provided that any cash Investments
by Borrower do not exceed

$250,000 in the aggregate in any fiscal year;

 

		(xii)	Investments consisting of Permitted Acquisitions; and

 

(xiii)  
additional Investments that do not exceed $250,000 in the aggregate.

 

“Permitted Liens” means:

 

		(i)	Liens in favor of Agent or the Lenders;

 

		(ii)	Liens existing on the Closing Date which are disclosed in Schedule 1C;

 

(iii)      
Liens for taxes, fees, assessments or other governmental charges or levies, either not yet due or being contested in good
faith by appropriate proceedings diligently conducted; provided, that Borrower maintains adequate reserves therefor on Borrower’s
Books in accordance with GAAP;

 

    	10

    	 

    

 

(iv)      
Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons
arising in the ordinary course of Borrower’s business and imposed without action of such parties; provided, that the payment
thereof is not yet required;

 

(v)        
Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder;

 

(vi)      
the following deposits, to the extent made in the ordinary course of business: deposits under worker’s compensation,
unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other
than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids,
tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than Liens arising
under ERISA or environmental Liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds;

 

(vii)    
Liens on Equipment or software or other intellectual property constituting purchase money Liens and other Liens in connection
with capital leases securing Indebtedness permitted in clause (iii) of “Permitted Indebtedness”;

 

		(viii)	Liens incurred in connection with Subordinated Indebtedness;

 

(ix)      
leasehold interests in leases or subleases and licenses granted in the ordinary course of business and not interfering in
any material respect with the business of the licensor;

 

(x)        
Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are
promptly paid on or before the date they become due;

 

(xi)      
Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before the
date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets);

 

(xii)    
statutory and common law rights of set-off and other similar rights as to deposits of cash and securities in favor of banks,
other depository institutions and brokerage firms;

 

(xiii)  
easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the
ordinary course of business so long as they do not materially impair the value or marketability of the related property;

 

(xiv)  
(A) Liens on Cash securing obligations permitted under clause (vii) of the definition of Permitted Indebtedness and (B)
security deposits in connection with real property leases, the combination of (A) and (B) in an aggregate amount not to exceed
$250,000 at any time;

 

(xv)    
Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of the type
described in clauses (i) through (xi) above; provided, that any extension, renewal or replacement Lien shall be limited to the
property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or refinanced (as
may have been reduced by any payment thereon) does not increase; and

 

    	11

    	 

    

 

(xvi)  
Other Liens, provided that the aggregate outstanding amount of Indebtedness secured thereby shall not exceed $150,000 at
any time.

 

“Permitted Transfers” means:

 

		(i)	sales of Inventory in the ordinary course of business,

 

(ii)        
licenses of, and similar arrangements for, Intellectual Property pursuant to the Option Agreement;

 

(iii)      
licenses and similar arrangements for the use of Intellectual Property in the ordinary course of business that could not
result in a legal transfer of title of the licensed property that may be exclusive in respects other than territory or may be exclusive
as to territory but only as to discreet geographical areas outside of the United States of America in the ordinary course of business,

 

(iv)      
dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business,

 

(v)        
transfers of assets made by Borrower or any of its Subsidiaries to another Borrower or any Subsidiary that is a Borrower
or guarantor hereunder;

 

(vi)      
other transfers of assets having a fair market value of not more than $500,000 in the aggregate in any fiscal year, and

 

(vii)    
Transfers which are Permitted Liens, Permitted Investments or distributions permitted under Section 7.7 of this Agreement.

 

“Person” means any
individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited
liability company, institution, other entity or government.

 

“Pledge Agreement”
means the Pledge Agreement dated as of the Closing Date between Borrower and Agent, as the same may from time to time be amended,
restated, modified or otherwise supplemented.

 

“Receivables”
means (i) all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit, proceeds
of any letter of credit, and Letter of Credit Rights, and (ii) all customer lists, software, and business records related thereto.

 

“Register” has the meaning specified in
Section 11.7.

 

“Required Lenders”
means at any time, the holders of more than 50% of the aggregate unpaid principal amount of the Term Loans then outstanding.

 

“Restricted License”
means any material License or other material agreement with respect to which Borrower is the licensee (a) that prohibits or otherwise
restricts Borrower from granting a security interest in Borrower’s interest in such License or agreement or any other property,
or (b) for which a default under or termination of could interfere with the Agent’s right to sell any Collateral.

 

    	12

    	 

    

 

“Sanctioned Country”
means, at any time, a country or territory which is the subject or target of any Sanctions.

 

“Sanctioned Person”
means, at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign
Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations Security Council,
the European Union or any EU member state, (b) any Person operating, organized or resident in a Sanctioned Country or (c) any Person
controlled by any such Person.

 

“Sanctions” means
economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government,
including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department
of State, or (b) the United Nations Security Council, the European Union or Her Majesty’s Treasury of the United Kingdom.

 

“Secured Obligations”
means Borrower’s obligations under this Agreement and any Loan Document (other than the Warrant), including any obligation
to pay any amount now owing or later arising.

 

“Subordinated Indebtedness”
means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory to Agent in its
reasonable discretion and subject to a subordination agreement in form and substance satisfactory to Agent in its reasonable discretion.

 

“Subsequent Financing”
means the closing of any Borrower financing which becomes effective after the Closing Date broadly marketed to multiple investors.

 

“Subsidiary” means
an entity, whether a corporation, partnership, limited liability company, joint venture or otherwise, in which Borrower owns or
controls 50% or more of the outstanding voting securities, including each entity listed on Schedule 1 hereto.

 

“Taxes” means all present
or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges
imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

 

“Term Commitment” means
as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to the Borrower in a principal amount not
to exceed the amount set forth under the heading “Term Commitment” opposite such Lender’s name on Schedule 1.1.

 

“Term Loan Advance”
means each Tranche 1 Advance, Tranche 2 Advance, Tranche 3 Advance and any other Term Loan funds advanced under this Agreement.

 

“Term
Loan Interest Rate” means for any day a per annum rate of interest equal to the greater of either (i) the sum of (x) the
prime rate as reported in The Wall Street Journal, and (y) Six and Thirty One Hundredths Percent (6.30%); or (ii) Nine and Fifty-Five
One Hundredths Percent (9.55%).

 

“Term Loan Maturity Date”
means April 1, 2024; provided that if such day is not a Business Day, the Term Loan Maturity Date shall be the immediately preceding
Business Day.

 

    	13

    	 

    

  

“Trademark License”
means any written agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter acquired
by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

“Trademarks” means all
trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings
and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States of America,
any State thereof or any other country or any political subdivision thereof.

 

“Tranche 3 Facility
Charge” means one percent (1.00%) of the Tranche 3 Advance, which is payable to the Lenders in accordance with Section 4.2(d).

 

“UCC” means the
Uniform Commercial Code as the same is, from time to time, in effect in the State of California; provided, that in the event that,
by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to,
Agent’s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in
a jurisdiction other than the State of California, then the term “UCC” shall mean the Uniform Commercial Code as in
effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment,
perfection, priority or remedies and for purposes of definitions related to such provisions.

 

“U.S. Person” means any
Person that is a “United States person” as defined in Section 7701(a)(30) of the Code.

 

“Warrant” means any
warrant entered into in connection with the Loan, as may be amended, restated or modified from time to time.

 

		1.2	The following terms are defined in the Sections or subsections referenced opposite such

terms:

 

	Defined Term	Section
	Agent	Preamble
	Assignee	11.14
	Borrower	Preamble
	Claims	11.11
	Collateral	3.1
	Confidential Information	11.13
	End of Term Charge	2.6
	Event of Default	9
	Financial Statements	7.1
	Indemnified Person	6.3
	Lenders	Preamble
	Liabilities	6.3
	Maximum Rate	2.3
	Open Source License	5.10
	Participant Register	11.8
	Prepayment Charge	2.5
	Publicity Materials	11.19

  

    	14

    	 

    

  

	Register	11.7
	Rights to Payment	3.1
	Tranche 1 Advance	2.2(a)
	Tranche 2 Advance	2.2(a)
	Tranche 3 Advance	2.2(a)

 

1.3             
Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,”
 “subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding
Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless otherwise specifically provided herein, any accounting
term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP
as in effect on the date hereof, and all financial computations hereunder shall be computed in accordance with GAAP as in effect
on the date hereof, consistently applied. Unless otherwise defined herein or in the other Loan Documents, terms that are used herein
or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC. For all purposes under
the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different
jurisdiction’s laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation
or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent
Person and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date
of its existence by the holders of its Equity Interests at such time.

 

1.4             
If at any time any change in GAAP would affect the computation of any financial requirement set forth in any Loan Document,
and either the Borrower or the Required Lenders shall so request, Agent, Lenders and the Borrower shall negotiate in good faith
to amend such requirement to preserve the original intent thereof in light of such change in GAAP; provided that, until so amended,
such requirement shall continue to be computed in accordance with GAAP prior to such change.

 

SECTION
2. THE LOAN

 

		2.1	[Reserved]

 

		2.2	Term Loan.

 

(a)               
Advances. Subject to the terms and conditions of this Agreement, the Lenders will severally (and not jointly) make in an
amount not to exceed its respective Term Commitment, and Borrower agrees to draw, a Term Loan Advance of Ten Million Dollars ($10,000,000)
on the Closing Date (the “Tranche 1 Advance”). Subject to the terms and conditions of this Agreement, beginning on
the later of (i) January 1, 2021 and (ii) the achievement of Performance Milestone I, and continuing through September 30, 2021
(as such date may be extended in Agent’s sole discretion), Borrower may request and the Lenders shall severally (and not
jointly) make an additional Term Loan Advance in a principal amount of Ten Million Dollars ($10,000,000) (the “Tranche 2
Advance”). Subject to the terms and conditions of this Agreement, and conditioned on approval by the Lenders’ investment
committee in its sole and unfettered discretion, Borrower may request additional Term Loan Advances in an aggregate principal amount
up to Ten Million Dollars ($10,000,000), in minimum increments of Two 

 

    	15

    	 

    

   

Million Five Hundred Thousand Dollars ($2,500,000)
(each, a “Tranche 3 Advance”). The aggregate outstanding Term Loan Advances may be up to the Maximum Term Loan Amount.

 

(b)                
Advance Request. To obtain a Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request (at least five
(5) Business Days before the Advance Date other than the Closing Date, which shall be at least one (1) Business Day) to Agent.
The Lenders shall fund the Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions
precedent to such Term Loan Advance is satisfied as of the requested Advance Date.

 

(c)               
Interest. Term Loan Interest Rate. The unpaid principal balance of each Term Loan Advance shall bear interest thereon from
such Advance Date until paid in full at the Term Loan Interest Rate based on a year consisting of 360 days, based on the actual
number of days elapsed. The Term Loan Interest Rate will float and change on the day the prime rate changes from time to time.

 

(d)              
Payment. Borrower will pay interest on each Term Loan Advance on the first Business Day of each month, beginning the month
after the Advance Date. Borrower shall repay the aggregate Term Loan principal balance that is outstanding on the day immediately
preceding the Amortization Date, in equal monthly installments of principal and interest (mortgage style) beginning on the Amortization
Date and continuing on the first Business Day of each month thereafter until the Secured Obligations (other than inchoate indemnity
obligations) are repaid. The entire Term Loan principal balance and all accrued but unpaid interest hereunder, shall be due and
payable on the Term Loan Maturity Date. Subject to Addendum 1, Borrower shall make all payments under this Agreement without setoff,
recoupment or deduction and regardless of any counterclaim or defense. If a payment hereunder becomes due and payable on a day
that is not a Business Day, the due date thereof shall be the immediately preceding Business Day. The Lenders will initiate debit
entries to the Borrower’s account as authorized on the ACH Authorization (i) on each payment date of all periodic obligations
payable to the Lenders under each Term Loan Advance and (ii) out-of-pocket legal fees and costs incurred by Agent or the Lenders
in connection with Section 11.12 of this Agreement; provided that, with respect to clause

(i) 
above, in the event that the Lenders or Agent informs Borrower that the Lenders will not initiate a debit entry to Borrower’s
account for a certain amount of the periodic obligations due on a specific payment date, Borrower shall pay to the Lenders such
amount of periodic obligations in full in immediately available funds on such payment date; provided, further, that, with respect
to clause (i) above, if the Lenders or Agent informs Borrower that the Lenders will not initiate a debit entry as described above
later than the date that is three (3) Business Days prior to such payment date, Borrower shall pay to the Lenders such amount of
periodic obligations in full in immediately available funds on the date that is three (3) Business Days after the date on which
the Lenders or Agent notifies Borrower of such; provided, further, that, with respect to clause (ii) above, (x) in the event that
the Lenders or Agent informs Borrower that the Lenders will not initiate a debit entry to Borrower’s account for certain
amount of such out-of-pocket legal fees and costs incurred by Agent or the Lenders, Borrower shall pay to the Lenders such amount
in full in immediately available funds within three (3) Business Days; and (y) except with respect to Agent’s and the Lenders’
fees and expenses necessary to finalize the loan documentation, and due and payable on the Closing Date, Agent shall provide Borrower
prior written notice before initiating a debit entry for payment of Agent’s and the Lenders’ fees and expenses due
after the Closing Date.

 

2.3             
Maximum Interest. Notwithstanding any provision in this Agreement or any other Loan Document, it is the parties’ intent
not to contract for, charge or receive interest at a rate that

 

    	16

    	 

    

  

 is greater than the maximum rate permissible
by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall
be deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”). If a
court of competent jurisdiction shall finally determine that Borrower has actually paid to the Lenders an amount of interest in
excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum
Rate, then such excess interest actually paid by Borrower shall be applied as follows: first, to the payment of the Secured Obligations
consisting of the outstanding principal; second, after all principal is repaid, to the payment of the Lenders’ accrued interest,
costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the
excess (if any) shall be refunded to Borrower.

 

2.4             
Default Interest. In the event any payment is not paid on the scheduled payment date, an amount equal to four percent (4%)
of the past due amount shall be payable on demand made by Agent in writing. In addition, upon the occurrence and during the continuation
of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional
fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.2(c), plus four percent (4%) per annum.
In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest
on interest, compounded at the rate set forth in Section 2.2(c) or this Section 2.4, as applicable.

 

2.5             
Prepayment. At its option, upon at least seven (7) Business Days prior written notice to Agent, Borrower may at any time
prepay all or a portion of the outstanding Advances by paying the entire principal balance (or such portion thereof), all accrued
and unpaid interest thereon, together with a prepayment charge equal to the following percentage of the principal amount of the
Advance being prepaid: with respect to each Advance, if such Advance amounts are prepaid prior to the Amortization Date, two percent
(2.00%); and thereafter, one percent (1.00%) (each, a “Prepayment Charge”); provided that any partial prepayment shall
be in minimum increments of principal in the amount $5,000,000 (or such lesser amount as is then outstanding). Borrower agrees
that the Prepayment Charge is a reasonable calculation of the Lenders’ lost profits in view of the difficulties and impracticality
of determining actual damages resulting from an early repayment of the Advances. Borrower shall prepay the outstanding amount of
all principal and accrued interest through the prepayment date and the Prepayment Charge upon the occurrence of a Change in Control
or any other prepayment hereunder. Notwithstanding the foregoing, Agent and the Lenders agree to waive the Prepayment Charge if
Agent and the Lenders (in their sole and absolute discretion) agree in writing to refinance the Advances prior to the Term Loan
Maturity Date. Any amounts paid under this Section shall be applied by Agent to the then unpaid amount of any Secured Obligations
(including principal and interest) in such order and priority as Agent may choose in its sole discretion. For the avoidance of
doubt, if a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately
preceding Business Day.

 

		2.6	End of Term Charge.

 

(a)            
On any date that Borrower partially prepays the outstanding Secured Obligations pursuant to Section 2.5, Borrower shall
pay the Lenders a charge of Three and Ninety-Five Hundredths Percent (3.95%) of such Term Loan Advances being repaid.

 

(b)           
On the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding Secured
Obligations (other than any inchoate indemnity 

 

    	17

    	 

    

  

obligations and any other obligations which,
by their terms, are to survive the termination of this Agreement) in full, or (iii) the date that the Secured Obligations become
due and payable, Borrower shall pay the Lenders a charge equal to (x) Three and Ninety-Five Hundredths Percent (3.95%) of the aggregate
Term Loan Advances minus (y) the aggregate amount of payments made pursuant to Section 2.6(a) (collectively with any charge made
pursuant to Section 2.6(a), the “End of Term Charge”).

 

(c)            
Notwithstanding the required payment date of such End of Term Charge, the applicable pro rata portion of the End of Term
Charge shall be deemed earned by the Lenders as of each date a Term Loan Advance is made. For the avoidance of doubt, if a payment
hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding
Business Day.

 

2.7             
Pro Rata Treatment. Each payment (including any prepayment) on account of any fee and any reduction of the Term Loans shall
be made pro rata according to the Term Commitments of the relevant Lender.

 

2.8             
Taxes; Increased Costs. The Borrower, the Agent and the Lenders each hereby agree to the terms and conditions set forth
on Addendum 1 attached hereto.

 

2.9             
Treatment of Prepayment Charge and End of Term Charge. Borrower agrees that any Prepayment Charge and any End of Term Charge
payable shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, and Borrower
agrees that it is reasonable under the circumstances currently existing and existing as of the Closing Date. The Prepayment Charge
and the End of Term Charge shall also be payable in the event the Secured Obligations (and/or this Agreement) are satisfied or
released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure, or by any other means. Borrower
expressly waives (to the fullest extent it may lawfully do so) the provisions of any present or future statute or law that prohibits
or may prohibit the collection of the foregoing Prepayment Charge and End of Term Charge in connection with any such acceleration.
Borrower agrees (to the fullest extent that each may lawfully do so): (a) each of the Prepayment Charge and the End of Term Charge
is reasonable and is the product of an arm’s length transaction between sophisticated business people, ably represented by
counsel; (b) each of the Prepayment Charge and the End of Term Charge shall be payable notwithstanding the then prevailing market
rates at the time payment is made; (c) there has been a course of conduct between the Lenders and Borrower giving specific consideration
in this transaction for such agreement to pay the Prepayment Charge and the End of Term Charge as a charge (and not interest) in
the event of prepayment or acceleration; (d) Borrower shall be estopped from claiming differently than as agreed to in this paragraph.
Borrower expressly acknowledges that their agreement to pay each of the Prepayment Charge and the End of Term Charge to the Lenders
as herein described was on the Closing Date and continues to be a material inducement to the Lenders to provide the Term Loans.

 

SECTION
3. SECURITY INTEREST

 

3.1             
As security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the Secured
Obligations, Borrower grants to Agent a security interest in all of Borrower’s right, title, and interest in, to and under
all of Borrower’s personal property and other assets including without limitation the following (except as set forth herein)
whether now owned or hereafter acquired (collectively, the “Collateral”): (a) Receivables; (b) Equipment; (c) Fixtures;
(d) General Intangibles (other than Intellectual Property); (e) Inventory; (f)

 

    	18

    	 

    

 

 Investment Property; (g) Deposit Accounts;
(h) Cash; (i) Goods; and all other tangible and intangible personal property of Borrower whether now or hereafter owned or existing,
leased, consigned by or to, or acquired by, Borrower and wherever located, and any of Borrower’s property in the possession
or under the control of Agent; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions
to, substitutions and replacements for, and rents, profits and products of each of the foregoing; provided, however, that
the Collateral shall include all Accounts and General Intangibles that consist of rights to payment and proceeds from the sale,
licensing or disposition of all or any part, or rights in, the Intellectual Property (the “Rights to Payment”). Notwithstanding
the foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual
Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective
as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of Agent’s
security interest in the Rights to Payment.

 

3.2             
Notwithstanding the broad grant of the security interest set forth in Section 3.1, above, the Collateral shall not include
(a) nonassignable licenses or contracts, which by their terms require the consent of the licensor thereof or another party (but
only to the extent such prohibition on transfer is enforceable under applicable law, including, without limitation, Sections 9406,
9407 and 9408 of the UCC), provided further, that upon the termination of such prohibition or such consent being provided with
respect to any license or contract, such license or contract shall automatically be included in the Collateral; (b) property for
which the granting of a security interest therein is contrary to applicable law, provided that upon the cessation of any such restriction
or prohibition, such property shall automatically be included in the Collateral; (c) any property subject to a Permitted Lien hereunder,
if the grant of a security interest with respect to such property pursuant to this Agreement would be prohibited by the agreement
creating such Permitted Lien or would otherwise constitute a default thereunder or create a right of termination by a party thereto
(other than Borrower), provided that upon the termination and release of such Lien or prohibition, such property shall automatically
be included in the Collateral; and (d) any Excluded Account.

 

SECTION
4. CONDITIONS PRECEDENT TO LOAN

 

The obligations of the Lenders
to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions:

 

4.1             
Initial Advance. On or prior to the Closing Date, Borrower shall have delivered to Agent the following:

 

(a)               
executed copies of the Loan Documents (other than the Warrant, which shall be an original), Account Control Agreements,
and all other documents and instruments reasonably required by Agent to effectuate the transactions contemplated hereby or to create
and perfect the Liens of Agent with respect to all Collateral, in all cases in form and substance reasonably acceptable to Agent;

 

(b)              
a legal opinion of Borrower’s counsel in form and substance reasonably acceptable to Agent,

 

(c)               
certified copy of resolutions of Borrower’s Board of Managers evidencing approval of (i) the Loan and other transactions
evidenced by the Loan Documents; and (ii) the Warrant and transactions evidenced thereby;

 

    	19

    	 

    

 

(d)              
certified copies of the Certificate of Formation Operating Agreement, as amended through the Closing Date, of Borrower;

 

(e)               
a certificate of good standing for Borrower from its state of formation and similar certificates from all other jurisdictions
in which it does business and where the failure to be qualified could have a Material Adverse Effect;

 

(f)               
payment of the Due Diligence Fee, Initial Facility Charge and reimbursement of Agent’s and the Lenders’ current
expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance;

 

(g)               
all certificates of insurance and copies of each insurance policy required hereunder; and

 

(h)               
such other documents as Agent may reasonably request.

 

		4.2	All Advances. On each Advance Date:

 

(a)               
Agent shall have received (i) an Advance Request for the relevant Advance as required by Section 2.2(b), each duly executed
by Borrower’s Chief Executive Officer or Chief Financial Officer, and (ii) any other documents Agent may reasonably request.

 

(b)              
The representations and warranties set forth in this Agreement shall be true and correct in all material respects (or, in
the case of any representation and warranty qualified by materiality, in all respects) on and as of the Advance Date with the same
effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier
date (in which case such representations and warranties shall be true and correct in all material respects as of such earlier date,
or, in the case of any representation and warranty qualified by materiality, in all respects as of such earlier date).

 

(c)               
Borrower shall be in compliance in all material respects with all the terms and provisions set forth herein and in each
other Loan Document on its part to be observed or performed, and at the time of and immediately after such Advance no Event of
Default shall have occurred and be continuing.

 

(d)              
With respect to any Tranche 3 Advance, the Loan Parties shall have paid the Tranche 3 Facility Charge.

 

(e)               
Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date
as to the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request.

 

4.3               
No Default. As of the Closing Date and each Advance Date, (i) no fact or condition exists that could (or could, with the
passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no event that has had or could reasonably
be expected to have a Material Adverse Effect has occurred and is continuing.

 

SECTION
5. REPRESENTATIONS AND WARRANTIES OF BORROWER

 

Borrower represents and warrants that:

 

    20

     

    

 

5.1             
Status. Borrower is a limited liability company duly organized, legally existing and in good standing under the laws its
state of formation, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or
location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have
a Material Adverse Effect. Borrower’s present name, former names (if any), locations, place of formation, Tax identification
number, organizational identification number and other information are correctly set forth in Exhibit B, as may be updated by Borrower
in a written notice (including any Compliance Certificate) provided to Agent after the Closing Date.

 

5.2             
Collateral. Borrower owns or otherwise has the rights to use the Collateral and owns, or has rights to, the Intellectual
Property, free of all Liens, except for Permitted Liens. Borrower has the power and authority to grant to Agent a Lien in the Collateral
as security for the Secured Obligations.

 

5.3             
Consents. Borrower’s execution, delivery and performance of this Agreement and all other Loan Documents, and Borrower’s
execution of the Warrant, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in
the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement
and the other Loan Documents, (iii) do not violate any provisions of Borrower’s Certificate of Formation, Operating Agreement,
or any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject, which could not reasonably be
expected to result in a Material Adverse Effect and (iv) except as described on Schedule 5.3, do not violate any material contract
or agreement or require the consent or approval of any other Person which has not already been obtained. The individual or individuals
executing the Loan Documents and the Warrant are duly authorized to do so.

 

5.4             
Material Adverse Effect. No event that has had or could reasonably be expected to have a Material Adverse Effect has occurred
and is continuing. Borrower is not aware of any event likely to occur that is reasonably expected to result in a Material Adverse
Effect.

 

5.5             
Actions Before Governmental Authorities. There are no actions, suits or proceedings at law or in equity or by or before
any Governmental Authority now pending or, to the knowledge of Borrower, threatened against or affecting Borrower or its property,
that is reasonably expected to result in a Material Adverse Effect.

 

		5.6	Laws.

 

(a)            
Neither Borrower nor any of its Subsidiaries is in violation of any law, rule or regulation, or in default with respect
to any judgment, writ, injunction or decree of any Governmental Authority, where such violation or default could reasonably be
expected to result in a Material Adverse Effect. Borrower is not in default in any manner under any provision of any agreement
or instrument evidencing material Indebtedness, or any other material agreement to which it is a party or by which it is bound.

 

(b)           
Neither Borrower nor any of its Subsidiaries is an “investment company” or a company “controlled”
by an “investment company” under the Investment Company Act of 1940, as amended. Neither Borrower nor any of its Subsidiaries
is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal
Reserve Board of Governors). Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair
Labor Standards Act. Neither Borrower nor any of its Subsidiaries 

 

    	21

    	 

    

 

is a “holding company” or an “affiliate”
of a “holding company” or a “subsidiary company” of a “holding company” as each term is defined
and used in the Public Utility Holding Company Act of 2005. Neither Borrower’s nor any of its Subsidiaries’ properties
or assets has been used by Borrower or such Subsidiary or, to Borrower’s Knowledge, by previous Persons, in disposing, producing,
storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws. Borrower and
each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and
given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.

 

(c)            
None of Borrower, any of its Subsidiaries, or to their knowledge, any of Borrower’s or its Subsidiaries’ respective
controlled Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions
contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engaging in or conspiring to engage in any transaction
that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any
Anti-Terrorism Law, or (iii) is a Blocked Person. None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and
any of their controlled Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated
by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to
or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or
interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law. None
of the funds to be provided under this Agreement will be used, directly or indirectly, (a) for any activities in violation of any
applicable anti-money laundering, economic sanctions and anti-bribery laws and regulations laws and regulations or (b) for any
payment to any governmental official or employee, political party, official of a political party, candidate for political office,
or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage,
in violation of the United States Foreign Corrupt Practices Act of 1977, as amended.

 

5.7             
Information Correct and Current. No information, report, Advance Request, financial statement, exhibit or schedule furnished,
by or on behalf of Borrower to Agent in connection with any Loan Document or included therein or delivered pursuant thereto contained,
or, when taken as a whole, contains or will contain any material misstatement of fact or, when taken together with all other such
information or documents, omitted, omits or will omit to state any material fact necessary to make the statements therein, in the
light of the circumstances under which they were, are or will be made, not materially misleading at the time such statement was
made or deemed made. Additionally, any and all financial or business projections provided by Borrower to Agent, whether prior to
or after the Closing Date, shall be (i) provided in good faith and based on the most current data and information available to
Borrower, and (ii) the most current of such projections provided to Borrower’s Board of Managers.

 

5.8             
Tax Matters. Except as described on Schedule 5.8, (a) Borrower and its Subsidiaries have filed all federal and state income
Tax returns and other material Tax returns that they are required to file (taking into account any timely filed extensions), (b)
Borrower and its Subsidiaries have duly paid all federal and state income Taxes and other material Taxes or installments thereof
that they are required to pay, except Taxes being contested in good faith by appropriate proceedings and for which Borrower and
its Subsidiaries maintain adequate reserves in accordance with GAAP, and (c) to the best of Borrower’s knowledge, no proposed
or pending Tax assessments, deficiencies, audits or other proceedings with respect to Borrower or any Subsidiary

 

    	22

    	 

    

  

 have had, or could reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect.

 

5.9             
Intellectual Property Claims. Borrower owns, or otherwise has the right to use, the Intellectual Property material to Borrower’s
business. Except as described on Schedule 5.9, (i) to the knowledge of Borrower, each of the material Copyrights, Trademarks and
Patents is valid and enforceable, (ii) no material part of the Intellectual Property has been judged invalid or unenforceable,
in whole or in part, and (iii) no claim has been made to Borrower that any material part of the Intellectual Property violates
the rights of any third party. Exhibit C is a true, correct and complete list of each of Borrower’s Patents, registered Trademarks,
registered Copyrights, and material agreements under which Borrower licenses Intellectual Property from third parties (other than
shrink-wrap software licenses), together with application or registration numbers, as applicable, owned by Borrower or any Subsidiary,
in each case as of the Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations
under, any of the foregoing contracts, licenses or agreements and, to Borrower’s knowledge, no third party to any such contract,
license or agreement is in material breach thereof or has failed to perform any material obligations thereunder.

 

5.10         
Intellectual Property. Except as described on Schedule 5.10, Borrower has all material rights with respect to Intellectual
Property necessary or material in the operation or conduct of Borrower’s business as currently conducted and proposed to
be conducted by Borrower. Without limiting the generality of the foregoing, and in the case of Licenses, except for restrictions
that are unenforceable under Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower’s
business, to freely transfer, license or assign Intellectual Property necessary or material in the operation or conduct of Borrower’s
business as currently conducted and proposed to be conducted by Borrower, without condition, restriction or payment of any kind
(other than license payments in the ordinary course of business) to any third party, and Borrower owns or has the right to use,
pursuant to valid licenses, all software development tools, library functions, compilers and all other third-party software and
other items that are necessary or material in the operation or conduct of Borrower’s business and used in the design, development,
promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products except customary covenants in inbound
license agreements and equipment leases where Borrower is the licensee or lessee. Except as set forth on Schedule 5.10, Borrower
is not a party to, nor is it bound by, any Restricted License.

 

No
material software or other materials used by Borrower or any of its Subsidiaries (or used in any Borrower Products or any Subsidiaries’
products) are subject to an open-source or similar license (including but not limited to the General Public License, Lesser General
Public License, Mozilla Public License, or Affero License) (collectively, “Open Source Licenses”) in a manner that
would cause such software or other materials to have to be (i) distributed to third parties at no charge or a minimal charge (royalty-free
basis); (ii) licensed to third parties to modify, make derivative works based on, decompile, disassemble, or reverse engineer;
or (iii) used in a manner that could require disclosure or distribution in source code form.

 

5.11         
Borrower Products. Except as described on Schedule 5.11, no Intellectual Property owned by Borrower or Borrower Product
has been or is subject to any actual or, to the knowledge of Borrower, threatened litigation, proceeding (including any proceeding
in the United States Patent and Trademark Office or any corresponding foreign office or agency, except for routine prosecution
of such Intellectual Property in the United States Patent and Trademark Office or any corresponding foreign office or agency) or
outstanding decree, order, judgment, settlement 

 

    	23

    	 

    

  

agreement or stipulation that restricts in
any material manner Borrower’s use, transfer or licensing thereof or that may affect the validity, use or enforceability
thereof. There is no decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in connection
with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any future Intellectual Property
related to the operation or conduct of the business of Borrower or Borrower Products. Borrower has not received any written notice
or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning Borrower’s ownership in any
Intellectual Property material to Borrower’s business (or written notice of any claim challenging or questioning the ownership
in any licensed Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal or beneficial
ownership with respect thereto nor, to Borrower’s knowledge, is there a reasonable basis for any such claim. To the best
knowledge of Borrower, neither Borrower’s use of its Intellectual Property nor the production and sale of Borrower Products
infringes the intellectual property or other rights of others.

 

5.12         
Financial Accounts. Exhibit D, as may be updated by the Borrower in a written notice provided to Agent after the Closing
Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary
maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment
Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name
in which the account is held, a description of the purpose of the account, and the complete account number therefor.

 

5.13         
Employee Loans. Except as described on Schedule 5.13, Borrower has no outstanding loans to any employee, officer or director
of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by
a third party.

 

5.14         
Capitalization and Subsidiaries. Borrower’s capitalization as of the Closing Date is set forth on Schedule 5.14 annexed
hereto. Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments.
Attached as Schedule 5.14, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct
and complete list of each Subsidiary.

 

SECTION
6. INSURANCE; INDEMNIFICATION

 

6.1             
Coverage. Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence form,
against risks and in such amounts customarily insured against in Borrower’s line of business; provided that such policies
of insurance shall be provided to and reviewed and approved by Agent in its reasonable discretion. Such risks shall include the
risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the
terms of the indemnification agreement found in Section 6.3. So long as there are any Secured Obligations outstanding, Borrower
shall also cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage
howsoever caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject
to standard exceptions and deductibles. If Borrower fails to obtain the insurance called for by this Section 6.1, suffers or causes
any reduction in coverage amounts from that in existence as of the Closing Date or fails to pay any premium thereon or fails to
pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document or which may be required
to preserve the Collateral, Agent may obtain such insurance or make such payment, and all amounts so paid by Agent are immediately
due and 

 

    	24

    	 

    

  

payable, bearing interest at the then highest
rate applicable to the Secured Obligations, and secured by the Collateral. Agent will make reasonable efforts to provide Borrower
with notice of Agent obtaining such insurance at the time it is obtained or within a reasonable time thereafter. No payments by
Agent are deemed an agreement to make similar payments in the future or Agent’s waiver of any Event of Default.

 

6.2             
Certificates. Borrower shall deliver to Agent certificates of insurance that evidence Borrower’s compliance with its
insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Borrower’s insurance certificate
shall state Agent (shown as “Hercules Capital, Inc., as Agent”) is an additional insured for commercial general liability,
a lenders loss payable for all risk property damage insurance, subject to the insurer’s approval, and a lenders loss payable
for property insurance and additional insured for liability insurance for any future insurance that Borrower may acquire from such
insurer. Attached to the certificates of insurance will be additional insured endorsements for liability and lender’s loss
payable endorsements for all risk property damage insurance. All certificates of insurance will provide for a minimum of thirty
(30) days advance written notice to Agent of cancellation (other than cancellation for non-payment of premiums, for which ten (10)
days’ advance written notice shall be sufficient) or any other change adverse to Agent’s interests. Any failure of
Agent to scrutinize such insurance certificates for compliance is not a waiver of any of Agent’s rights, all of which are
reserved. Upon written request of Agent, Borrower shall provide Agent with copies of each insurance policy. Upon entering or amending
any insurance policy required hereunder, Borrower shall provide Agent with copies of such policies and shall promptly deliver to
Agent updated insurance certificates with respect to such policies.

 

6.3             
Indemnity. Borrower agrees to indemnify and hold Agent, the Lenders and their officers, directors, employees, agents, in-house
attorneys, representatives and shareholders (each, an “Indemnified Person”) harmless from and against any and all claims,
costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in
tort, including strict liability in tort), including reasonable and documented attorneys’ fees and disbursements and other
costs of investigation or defense (including those incurred upon any appeal) (collectively, “Liabilities”), that may
be instituted or asserted against or incurred by such Indemnified Person as the result of credit having been extended, suspended
or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or
arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith,
or arising out of the disposition or utilization of the Collateral. Notwithstanding anything contained herein to the contrary,
in no event shall Borrower be required to indemnify any Indemnified Person for any Liabilities to the extent such Liabilities arise
solely out of gross negligence or willful misconduct of any Indemnified Person. This Section 6.3 shall not apply with respect to
Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim. In no event shall any Indemnified
Person be liable on any theory of liability for any special, indirect, consequential or punitive damages (including any loss of
profits, business or anticipated savings). This Section 6.3 shall survive the repayment of indebtedness under, and otherwise shall
survive the expiration or other termination of, this Agreement.

 

SECTION
7. COVENANTS OF BORROWER

 

Borrower agrees as follows:

 

    25

     

    

 

7.1             
Financial Reports. Borrower shall furnish to Agent the financial statements and reports listed hereinafter (the “Financial
Statements”):

 

(a)               
as soon as practicable (and in any event within thirty (30) days) after the end of each month, unaudited interim and year-to-date
financial statements as of the end of such month (prepared on a consolidated basis), including balance sheet and related statements
of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material
litigation by or against Borrower) or any other occurrence that could reasonably be expected to have a Material Adverse Effect,
all certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared
in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year-end adjustments, and
(iii) they do not contain certain non-cash items that are customarily included in quarterly and annual financial statements;

 

(b)              
as soon as practicable (and in any event within forty-five (45) days) after the end of each calendar quarter, unaudited
interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated basis), including
balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including
the commencement of any material litigation by or against Borrower) or any other occurrence that could reasonably be expected to
have a Material Adverse Effect, certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the effect
that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to
normal year-end adjustments, as well as the most recent capitalization table for Borrower;

 

(c)               
as soon as practicable (and in any event within one hundred eighty (180) days (or, if Borrower becomes subject to reporting
rules of the United States Securities and Exchange Commission, ninety (90) days) after the end of each fiscal year, unqualified
audited financial statements as of the end of such year (prepared on a consolidated basis), including balance sheet and related
statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year,
certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Agent, accompanied
by any management report from such accountants;

 

(d)                
together with the financial statements delivered as required by Sections 7.1(a) through (c), a Compliance Certificate in
the form of Exhibit E;

 

(e)               
as soon as practicable (and in any event within 7 days) after the end of each month, a report showing agings of accounts
receivable and accounts payable;

 

(f)               
promptly after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements or
reports that Borrower has made available to holders of its units and copies of any regular, periodic and special reports or registration
statements that Borrower files with the United States Securities and Exchange Commission or any Governmental Authority that may
be substituted therefor, or any national securities exchange;

 

(g)               
promptly following execution thereof, copies of any material amendments or modifications to (i) the Commitment Agreement,
(ii) the Operating Agreement and/or (iii) the Option Agreement;

 

    	26

    	 

    

 

(h)              
financial and business projections promptly following their approval by Borrower’s Board of Managers, and in any event,
within thirty (30) days after to the end of Borrower’s fiscal year, as well as budgets, operating plans and other financial
information reasonably requested by Agent;

 

(i)                
a copy of Century’s, Borrower’s and their Subsidiaries’ annual 409A valuation report as soon as practicable
(and in any event, within ten (10) days after such report becomes available); and

 

(j)                
Immediate notice if Borrower or any Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower,
is listed on the OFAC Lists or (a) is convicted on,

(b) pleads nolo contendere to, (c) is indicted
on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.

 

Borrower shall not make any change in its (a) accounting
policies or reporting practices, except as required by GAAP or (b) fiscal years or fiscal quarters. The fiscal year of Borrower
shall end on December 31.

 

The executed Compliance Certificate, and all Financial
Statements required to be delivered pursuant to clauses (a), (b), (c) and (d) shall be sent via e-mail to financialstatements@htgc.com
with a copy to legal@htgc.com, bjadot@htgc.com, mdutra@htgc.com and ksegien@htgc.com provided,
that if e- mail is not available or sending such Financial Statements via e-mail is not possible, they shall be faxed to Agent
at: (650) 473-9194, attention Account Manager: Century Therapeutics, LLC.

Notwithstanding the foregoing, documents
required to be delivered under Sections 7.1(a), (b), (c) or (f) (to the extent any such documents are included in materials
otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on
the date on which Borrower emails a link thereto to Agent; provided that Borrower shall directly provide Agent all Financial
Statements required to be delivered pursuant to Section 7.1(b) and (c) hereunder.

7.2             
Management Rights. Borrower shall permit any representative that Agent or the Lenders authorizes, including their attorneys
and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower
at reasonable times and upon reasonable notice during normal business hours; provided, however, that so long as no Event
of Default has occurred and is continuing, such examinations shall be limited to no more often than once per fiscal year. In addition,
any such representative shall have the right to meet with management and officers of Borrower to discuss such books of account
and records. In addition, Agent or the Lenders shall be entitled at reasonable times and intervals to consult with and advise the
management and officers of Borrower concerning significant business issues affecting Borrower. Such consultations shall not unreasonably
interfere with Borrower’s business operations. The parties intend that the rights granted Agent and the Lenders shall constitute
 “management rights” within the meaning of 29 C.F.R. Section 2510.3-101(d)(3)(ii), but that any advice, recommendations
or participation by Agent or the Lenders with respect to any business issues shall not be deemed to give Agent or the Lenders,
nor be deemed an exercise by Agent or the Lenders of, control over Borrower’s management or policies.

 

7.3             
Further Assurances. Borrower shall from time to time execute, deliver and file, alone or with Agent, any financing statements,
security agreements, collateral assignments, notices, control agreements, promissory notes or other documents to perfect, give
the highest priority to Agent’s Lien on the Collateral or otherwise evidence Agent’s rights herein. Borrower shall
from time to time procure any instruments or documents as may be reasonably requested by 

 

    	27

    	 

    

  

Agent, and take all further action that may be
necessary, or that Agent may reasonably request, to perfect and protect the Liens granted hereby and thereby. In addition, and
for such purposes only, Borrower hereby authorizes Agent to execute and deliver on behalf of Borrower and to file such financing
statements (including an indication that the financing statement covers “all assets or all personal property” of Borrower
in accordance with Section 9-504 of the UCC), collateral assignments, notices, control agreements, security agreements and other
documents without the signature of Borrower either in Agent’s name or in the name of Agent as agent and attorney-in-fact
for Borrower. Borrower shall protect and defend Borrower’s title to the Collateral and Agent’s Lien thereon against
all Persons claiming any interest adverse to Borrower or Agent other than Permitted Liens.

 

7.4              Indebtedness.
Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any
Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on
Borrower an obligation to prepay any Indebtedness, except for (a) the conversion of Indebtedness into equity securities and
the payment of cash in lieu of fractional units in connection with such conversion, (b) purchase money Indebtedness pursuant
to its then applicable payment schedule, (c) prepayment by any Subsidiary of (i) inter-company Indebtedness owed by such
Subsidiary to any Borrower, or (ii)  if
such Subsidiary is not a Borrower, intercompany Indebtedness owed by such Subsidiary to another Subsidiary that is not a
Borrower, (d) payments made on Subordinated Indebtedness made in accordance with the terms of the relevant Subordination
Agreement, (e) scheduled payments on Permitted Indebtedness in accordance with the terms thereof or (f) as otherwise
permitted hereunder or approved in writing by Agent.

 

7.5             
Collateral. Borrower shall at all times keep the Collateral, the Intellectual Property and all other property and assets
used in Borrower’s business or in which Borrower now or hereafter holds any interest free and clear from any legal process
or Liens whatsoever (except for Permitted Liens), and shall give Agent prompt written notice of any legal process that is reasonably
likely to result in damages, expenses or liabilities in excess of $250,000, affecting the Collateral, the Intellectual Property,
such other property and assets, or any Liens thereon, provided however, that the Collateral and such other property and assets
may be subject to Permitted Liens except that there shall be no Liens whatsoever on Intellectual Property. Borrower shall not agree
with any Person other than Agent or the Lenders not to encumber its property. Borrower shall not enter into or suffer to exist
or become effective any agreement that prohibits or limits the ability of any Borrower to create, incur, assume or suffer to exist
any Lien upon any of its property (including Intellectual Property), whether now owned or hereafter acquired, to secure its obligations
under the Loan Documents to which it is a party other than (a) this Agreement and the other Loan Documents, (b) any agreements
governing any purchase money Liens or capital lease obligations otherwise permitted hereby (in which case, any prohibition or limitation
shall only be effective against the assets financed thereby) and (c) customary restrictions on the assignment of leases, licenses
and other agreements. Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its assets from
and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times
to keep such Subsidiary’s property and assets free and clear from any legal process or Liens whatsoever (except for Permitted
Liens, provided however, that there shall be no Liens whatsoever on Intellectual Property), and shall give Agent prompt written
notice of any legal process affecting such Subsidiary’s assets.

 

7.6             
Investments. Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit
any of its Subsidiaries to do so, other than Permitted Investments.

 

    	28

    	 

    

 

7.7              Distributions.
Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other Equity
Interest other than pursuant to employee, director, manager or consultant repurchase plans or other similar agreements,
provided, however, in each case the repurchase or redemption price does not exceed the original consideration paid for such
stock or Equity Interest, or (b) declare or pay any cash dividend or make any other cash distribution on any class of stock
or other Equity Interest, except that (x) a Subsidiary may pay dividends or make other distributions to Borrower or any
Subsidiary of Borrower and (y) Borrower may make distributions to its members in accordance with Section 7.03 of the
Operating Agreement on account of such members’ tax liability (including any required estimated tax payments) resulting
from such members’ membership interests in Borrower, in accordance with the terms of the Operating Agreement, or (c)
lend money to any employees, officers, managers or directors or guarantee the payment of any such loans granted by a third
party in excess of $100,000 in the aggregate or (d) waive, release or forgive any Indebtedness owed by any employees,
officers, managers or directors in excess of $100,000 in the aggregate.

 

7.8             
Transfers. Except for Permitted Transfers, Borrower shall not, and shall not allow any Subsidiary to, voluntarily or involuntarily
transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material
portion of its assets.

 

7.9             
Mergers and Consolidations. Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate,
with or into any other business organization (other than mergers or consolidations of (a) a Subsidiary which is not a Borrower
into another Subsidiary or into Borrower or (b) a Borrower into another Borrower).

 

7.10         
Taxes. Borrower shall, and shall cause each of its Subsidiaries to, pay when due (subject to any properly obtained extensions)
all material Taxes of any nature whatsoever now or hereafter imposed or assessed against Borrower or the Collateral or upon Borrower’s
ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom.
Borrower shall, and shall cause each of its Subsidiaries to, accurately file on or before the due date therefor (taking into account
proper extensions) all federal and state income Tax returns and other material Tax returns required to be filed. Notwithstanding
the foregoing, Borrower and its Subsidiaries may contest, in good faith and by appropriate proceedings diligently conducted, Taxes
for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP.

 

7.11          Organizational
Changes. Neither Borrower nor any Subsidiary shall change its name, legal form or jurisdiction of formation without twenty
(20) days’ prior written notice to Agent. Neither Borrower nor any Subsidiary shall suffer a Change in Control. Neither
Borrower nor any Subsidiary shall relocate its chief executive office or its principal place of business unless: (i) it has
provided prior written notice to Agent; and (ii) such relocation, except with respect to Century Canada, shall be within the
continental United States of America. Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than
(x) sales of Inventory in the ordinary course of business, (y) relocations of Equipment having an aggregate value of up to
$150,000 in any fiscal year, and (z) relocations of Collateral from a location described on Exhibit B to another location
described on Exhibit B) unless (i) it has provided prompt written notice to Agent, (ii) such relocation is within the
continental United States of America (except with respect to Century Canada) and, (iii) if such relocation is to a third
party bailee, it has delivered a bailee agreement in form and substance reasonably acceptable to Agent.

 

    	29

    	 

    

 

7.12         
Deposit Accounts. Neither Borrower nor any Subsidiary shall maintain any Deposit Accounts, or accounts holding Investment
Property, except with respect to which Agent has an Account Control Agreement; provided that no Account Control Agreement shall
be required for any Excluded Account.

 

7.13         
Borrower shall notify Agent of each Subsidiary formed subsequent to the Closing Date and, within 15 days of formation (or
such later date as Agent may agree in its sole discretion), shall cause any such Subsidiary to execute and deliver to Agent a Joinder
Agreement.

 

7.14         
Century Canada. Borrower shall not cause or permit Cash or other assets held by Century Canada to exceed $500,000 in the
aggregate at any time. Borrower shall not cause or permit Century Canada to incur any Indebtedness other than the Empirica Promissory
Note.

 

7.15         
Notification of Event of Default. Borrower shall notify Agent promptly, any in any event within three (3) Business Days,
of the occurrence of any Event of Default.

 

		7.16	[RESERVED]

 

7.17         
Use of Proceeds. Borrower agrees that the proceeds of the Loans shall be used solely to pay related fees and expenses in
connection with this Agreement and for working capital and general corporate purposes, including to fund any Permitted Investments.
The proceeds of the Loans Credit will not be used in violation of Anti-Corruption Laws or applicable Sanctions.

 

		7.18	[RESERVED].

 

		7.19	Compliance with Laws.

 

Borrower
shall maintain, and shall cause its Subsidiaries to maintain, compliance in all material respects with all applicable laws, rules
or regulations (including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations),
and shall, or cause its Subsidiaries to, obtain and maintain all required governmental authorizations, approvals, licenses, franchises,
permits or registrations reasonably necessary in connection with the conduct of Borrower’s business.

 

Neither
Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any controlled Affiliate to, directly
or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists.

Neither Borrower nor any of its Subsidiaries shall,
nor shall Borrower or any of its Subsidiaries, permit any controlled Affiliate to, directly or indirectly, (i) conduct any business
or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any
contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any
transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive
order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the
purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other
Anti-Terrorism Law.

 

Borrower
will, within 90 days of the Closing Date, implement and at all times thereafter maintain in effect policies and procedures designed
to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-
Corruption Laws and applicable Sanctions, and Borrower, its Subsidiaries and their respective 

 

    	30

    	 

    

  

officers and employees and to the knowledge of
Borrower its directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects.

 

None
of Borrower, any of its Subsidiaries or any of their respective managers, officers or employees, or to the knowledge of Borrower,
any agent for Borrower or its Subsidiaries that will act in any capacity in connection with or benefit from the credit facility
established hereby, is a Sanctioned Person. No Loan, use of proceeds or other transaction contemplated by this Agreement will violate
Anti-Corruption Laws or applicable Sanctions.

 

7.20         
Minimum Cash. If and only if Borrower has both: (a) drawn the Tranche 2 Advance and (b) not achieved Performance
Milestone II by September 30, 2021, then at all times after September 30, 2021, Borrower shall maintain minimum unrestricted Cash
of at least Eight Million Five Hundred Thousand Dollars ($8,500,000) plus the amount of Borrower’s accounts payable not paid
after the 90th day following the invoice date for such accounts payable, in an account subject to an Account Control Agreement
in favor of Agent, until Performance Milestone II has been achieved. For the avoidance of doubt, if the Tranche 2 Advance is not
drawn or Borrower has achieved Performance Milestone II by September 30, 2021, then there shall be no minimum cash requirement.

 

7.21         
Intellectual Property. Borrower shall (i) protect, defend and maintain the validity and enforceability of its Intellectual
Property; (ii) promptly advise Agent in writing of material infringements of its Intellectual Property; and (iii) not allow any
Intellectual Property material to Borrowers’ business to be abandoned, forfeited or dedicated to the public without Agent’s
written consent.

 

7.22         
Transactions with Affiliates. Except as described on Schedule 7.22, Borrower shall not and shall not permit any Subsidiary
to, directly or indirectly, enter into or permit to exist any transaction of any kind with any Affiliate of Borrower or such Subsidiary
on terms that are less favorable to Borrower or such Subsidiary, as the case may be, than those that might be obtained in an arm’s
length transaction from a Person who is not an Affiliate of Borrower or such Subsidiary.

 

SECTION
8. RIGHT TO INVEST

 

8.1       Borrower
shall use commercially reasonable efforts to notify the Lenders of each Subsequent Financing, and the Lenders or their assignee
or nominee shall have the right, in their discretion, to indicate their interest to participate in any Subsequent Financing on
the same terms, conditions and pricing afforded to investors participating in any such Subsequent Financing (excluding Bayer and
Century Therapeutics, Inc.). This Section 8.1, and all rights and obligations hereunder, shall expire upon termination of this
Agreement.

 

SECTION
9. EVENTS OF DEFAULT

 

The occurrence of any one or more of the following events
shall be an Event of Default:

 

9.1             
Payments. Borrower fails to pay any amount due under this Agreement or any of the other Loan Documents on the due date;
provided, however, that an Event of Default shall not occur on account of a failure to pay due solely to an administrative or operational
error of Agent or the Lenders or Borrower’s bank if Borrower had the funds to make the payment when due and makes the payment
within three (3) Business Days following Borrower’s knowledge of such failure to pay; or

 

    	31

    	 

    

 

9.2             
Covenants. Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement,
or any of the other Loan Documents or any other agreement among Borrower, Agent and the Lenders, and (a) with respect to a default
under any covenant under this Agreement (other than under Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.15, 7.17, 7.19, 7.20, 7.21,
and 7.22), any other Loan Document, or any other agreement among Borrower, Agent and the Lenders, such default continues for more
than ten (10) Business Days after the earlier of the date on which (i) Agent or the Lenders has given notice of such default to
Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 6, 7.4,
7.5, 7.6, 7.7, 7.8, 7.9, 7.15, 7.17, 7.19, 7.20, 7.21, and 7.22, the occurrence of such default; or

 

9.3             
Material Adverse Effect. A circumstance has occurred that could reasonably be expected to have a Material Adverse Effect;
or

 

9.4             
Representations. Any representation or warranty made by Borrower in any Loan Document or in the Warrant shall have been
false or misleading in any material respect when made or when deemed made; or

 

9.5             
Insolvency. Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts
as they become due, or be unable to pay or perform under the Loan Documents, or shall become insolvent; or (iii) shall file a voluntary
petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement,
composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent
to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator
of Borrower or of all or any substantial part of the assets or property of Borrower; or (vi) shall cease operations of its business
as its business has normally been conducted, or terminate substantially all of its employees; or (vii) Borrower or its directors
or majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi); or
(B) either

(i) forty-five (45) days shall have expired after
the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation,
dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all
orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any such
order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower
shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings;
or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings;
or (v) forty-five (45) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee,
receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such appointment being
vacated; or

 

9.6             
Attachments; Judgments. Any portion of Borrower’s assets is attached or seized, or a levy is filed against any such
assets, or a judgment or judgments is/are entered for the payment of money (not covered by independent third party insurance as
to which liability has not been rejected by such insurance carrier), individually or in the aggregate, of at least $100,000, or
Borrower is enjoined or in any way prevented by court order from conducting any part of its business; or

    	32

    	 

    

 

 

9.7             
Other Obligations. The occurrence of any default under any agreement or obligation of Borrower involving any Indebtedness
in excess of $100,000, or any other material agreement or obligation, in each case if a Material Adverse Effect could reasonably
be expected to result from such default.

 

SECTION
10. REMEDIES

 

10.1          General.
Upon the occurrence of any one or more Events of Default, Agent may, and at the direction of the Required Lenders shall,
accelerate and demand payment of all or any part of the Secured Obligations together with a Prepayment Charge and declare
them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in
Section 9.5, all of the Secured Obligations (including, without limitation, the Prepayment Charge and the End of Term Charge)
shall automatically be accelerated and made due and payable, in each case without any further notice or act). Borrower hereby
irrevocably appoints Agent as its lawful attorney-in-fact to: (a) exercisable following the occurrence of an Event of
Default, (i) sign Borrower’s name on any invoice or bill of lading for any account or drafts against account debtors;
(ii) demand, collect, sue, and give releases to any account debtor for monies due, settle and adjust disputes and claims
about the accounts directly with account debtors, and compromise, prosecute, or defend any action, claim, case, or proceeding
about any Collateral (including filing a claim or voting a claim in any bankruptcy case in Agent’s or Borrower’s
name, as Agent may elect); (iii) make, settle, and adjust all claims under Borrower’s insurance policies; (iv) pay,
contest or settle any Lien, charge, encumbrance, security interest, or other claim in or to the Collateral, or any judgment
based thereon, or otherwise take any action to terminate or discharge the same; (v) transfer the Collateral into the name of
Agent or a third party as the UCC permits; and (vi) receive, open and dispose of mail addressed to Borrower; and (b)
regardless of whether an Event of Default has occurred, (i) endorse Borrower’s name on any checks, payment instruments,
or other forms of payment or security; and (ii) notify all account debtors to pay Agent directly. Borrower hereby appoints
Agent as its lawful attorney-in-fact to sign Borrower’s name on any documents necessary to perfect or continue the
perfection of Agent’s security interest in the Collateral regardless of whether an Event of Default has occurred until
all Secured Obligations have been satisfied in full and the Loan Documents have been terminated. Agent’s foregoing
appointment as Borrower’s attorney in fact, and all of Agent’s rights and powers, coupled with an interest, are
irrevocable until all Secured Obligations have been fully repaid and performed and the Loan Documents have been terminated.
Agent may, and at the direction of the Required Lenders shall, exercise all rights and remedies with respect to the
Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right
to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral
and the right to occupy, utilize, process and commingle the Collateral. All Agent’s rights and remedies shall be
cumulative and not exclusive.

 

10.2         
Collection; Foreclosure. Upon the occurrence and during the continuance of any Event of Default, Agent may, and at the direction
of the Required Lenders shall, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or
otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation
or processing, in such order as Agent may elect. Any such sale may be made either at public or private sale at its place of business
or elsewhere. Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’ prior written notice
to Borrower. Agent may require Borrower to assemble the Collateral and make it available to Agent at a place designated by Agent
that is reasonably convenient to Agent and Borrower. The proceeds of any 

 

    	33

    	 

    

  

sale, disposition or other realization upon
all or any part of the Collateral shall be applied by Agent in the following order of priorities:

 

First, to Agent and the Lenders in an amount sufficient
to pay in full Agent’s and the Lenders’ reasonable costs and professionals’ and advisors’ fees and expenses
as described in Section 11.12;

Second, to the Lenders in an amount equal to
the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order
and priority as Agent may choose in its sole discretion; and

Finally, after the full and
final payment in Cash of all of the Secured Obligations (other than inchoate obligations), to any creditor holding a junior Lien
on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct.

Agent shall be deemed to
have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations
of a secured party under the UCC.

 

10.3         
No Waiver. Agent shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other
Person, and Borrower expressly waives all rights, if any, to require Agent to marshal any Collateral.

 

10.4         
Cumulative Remedies. The rights, powers and remedies of Agent hereunder shall be in addition to all rights, powers and remedies
given by statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided
herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Agent.

 

SECTION
11. MISCELLANEOUS

 

11.1         
Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision
shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such
provision or the remaining provisions of this Agreement.

 

11.2         
Notice. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process
or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the
Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served,
given, delivered, and received upon the earlier of: (i) the day of transmission by electronic mail or hand delivery or delivery
by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United
States of America mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows:

 

		(a)	If to Agent:

 

HERCULES CAPITAL, INC.

Legal Department

Attention: Chief Legal Officer and R. Bryan
Jadot 

400 Hamilton Avenue, Suite 310

 

    	34

    	 

    

 

Palo Alto, CA 94301

email: legal@htgc.com; bjadot@htgc.com;
mdutra@htgc.com and ksegien@htgc.com

Telephone: 650-289-3060

 

(b)          
If to the Lenders:

 

HERCULES CAPITAL, INC.

Legal Department

Attention: Chief Legal Officer and R. Bryan
Jadot 

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

email: legal@htgc.com; bjadot@htgc.com; mdutra@htgc.com
and ksegien@htgc.com

Telephone: 650-289-3060

 

		(c)	If to Borrower:

 

CENTURY THERAPEUTICS, LLC

Attention: Douglas Carr 

3675
Market Street

Philadelphia, PA 19104 

email: doug@centurytx.com

Telephone:

 

With a copy (which shall not constitute notice) to:

 

Troutman Pepper Hamilton Sanders LLP

Attention:
Rachael Bushey and Kathryn Nordick

3000 Two Logan Square

Philadelphia, PA 19103-2799

email: rachael.bushey@troutman.com; kathryn.nordick@troutman.com

 

or to such other address as each party may designate
for itself by like notice.

		11.3	Entire Agreement; Amendments.

 

(a)               
This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect
of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, non-disclosure
or confidentiality agreements, letters, negotiations or other documents or agreements, whether written or oral, with respect to
the subject matter hereof or thereof (including Agent’s revised proposal letter dated June 23, 2020 and the Non-Disclosure
Agreement).

 

(b)               Neither
this Agreement, any other Loan Document, nor any terms hereof or thereof may be amended, supplemented or modified except in
accordance with the provisions of this Section 11.3(b). The Required Lenders and Borrower party to the relevant Loan Document
may, or, with the written consent of the Required Lenders, the Agent and the Borrower party to the relevant Loan Document
may, from time to time, (i) enter into written amendments, supplements or modifications hereto and to the other Loan
Documents for the purpose of adding any provisions to this Agreement or the other Loan Documents or changing in any manner
the

 

    	35

    	 

    

  

 rights of the Lenders or of the Borrower hereunder or thereunder or (ii) waive, on such terms and conditions as the
Required Lenders or the Agent, as the case may be, may specify in such instrument, any of the requirements of this Agreement
or the other Loan Documents or any Default or Event of Default and its consequences; provided, however, that no such waiver
and no such amendment, supplement or modification shall (A) forgive the principal amount or extend the final scheduled date
of maturity of any Loan, extend the scheduled date of any amortization payment in respect of any Term Loan, reduce the stated
rate of any interest (or fee payable hereunder) or extend the scheduled date of any payment thereof, in each case without the
written consent of each Lender directly affected thereby; (B) eliminate or reduce the voting rights of any Lender under this
Section 11.3(b) without the written consent of such Lender; (C) reduce any percentage specified in the definition of Required
Lenders, consent to the assignment or transfer by the Borrower of any of its rights and obligations under this Agreement and
the other Loan Documents, release all or substantially all of the Collateral or release a Borrower from its obligations under
the Loan Documents, in each case without the written consent of all Lenders; or (D) amend, modify or waive any provision of
Section 11.18 or Addendum 3 without the written consent of the Agent. Any such waiver and any such amendment, supplement or
modification shall apply equally to each Lender and shall be binding upon Borrower, the Lender, the Agent and all future
holders of the Loans.

 

11.4         
No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement.
In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly
by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement.

 

11.5         
No Waiver. The powers conferred upon Agent and the Lenders by this Agreement are solely to protect its rights hereunder
and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Agent or the Lenders to
exercise any such powers. No omission or delay by Agent or the Lenders at any time to enforce any right or remedy reserved to it,
or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver
of any such right or remedy to which Agent or the Lenders is entitled, nor shall it in any way affect the right of Agent or the
Lenders to enforce such provisions thereafter.

 

11.6         
Survival. All agreements, representations and warranties contained in this Agreement and the other Loan Documents or in
any document delivered pursuant hereto or thereto shall be for the benefit of Agent and the Lenders and shall survive the execution
and delivery of this Agreement. Sections 6.3, 11.14, 11.15 and 11.18 shall survive the termination of this Agreement.

 

11.7         
Successors and Assigns. The provisions of this Agreement and the other Loan Documents shall inure to the benefit of and
be binding on Borrower and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement or any
of the other Loan Documents without Agent’s express prior written consent, and any such attempted assignment shall be void
and of no effect. Agent and the Lenders may assign, transfer, or endorse its rights hereunder and under the other Loan Documents
with prior notice to Borrower (as long as no Event of Default has occurred and is continuing), and all of such rights shall inure
to the benefit of Agent’s and the Lenders’ successors and assigns; provided that as long as no Event of Default has
occurred and is continuing, neither Agent nor any Lender may assign, transfer or endorse its rights hereunder or under the Loan
Documents to any party that is a direct competitor of Borrower (as 

 

    	36

    	 

    

  

identified in writing by Borrower to Agent or
otherwise reasonably determined by Agent), it being acknowledged that in all cases, any transfer to an Affiliate of any Lender
or Agent shall be allowed. Notwithstanding the foregoing, (x) in connection with any assignment by a Lender as a result of a forced
divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Agent and the Lenders
may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party, (y) in connection
with any assignment by a Lender the assigning Lender and the assignee Lender must provide the Agent with an information reasonably
required by the Agent in order to maintain the Register and (z) in connection with a Lender’s own financing or securitization
transactions, the restrictions set forth herein shall not apply and Agent and the Lenders may assign, transfer or indorse its rights
hereunder and under the other Loan Documents to any Person or party providing such financing or formed to undertake such securitization
transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence
with respect to such financing or securitization transaction; provided that no such sale, transfer, pledge or assignment under
this clause (z) shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such
Lender as a party hereto until Agent shall have received and accepted an effective assignment agreement from such Person or party
in form satisfactory to Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received
such other information regarding such assignee as Agent reasonably shall require. The Agent, acting solely for this purpose as
an agent of the Borrower, shall maintain at one of its offices in the United States a register for the recordation of the names
and addresses of the Lender(s), and the Term Commitments of, and principal amounts (and stated interest) of the Loans owing to,
each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive
absent manifest error, and the Borrower, the Agent and the Lender(s) shall treat each Person whose name is recorded in the Register
pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection
by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.

 

11.8         
Participations. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of
the Borrower, maintain a register on which it enters the name and address of each participant and the principal amounts (and stated
interest) of each participant’s interest in the Loans or other obligations under the Loan Documents (the “Participant
Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register
(including the identity of any participant or any information relating to a participant's interest in any commitments, loans, its
other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that
such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States
Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall
treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this
Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Agent (in its capacity as Agent) shall have
no responsibility for maintaining a Participant Register. Borrower agrees that each participant shall be entitled to the benefits
of the provisions in Addendum 1 attached hereto (subject to the requirements and limitations therein, including the requirements
under Section 7 of Addendum 1 attached hereto (it being understood that the documentation required under Section 7 of Addendum
1 attached hereto shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its
interest by assignment pursuant to Section 11.7; provided that such participant shall not be entitled to receive any greater payment
under Addendum 1 attached hereto, with respect to any participation, than its participating Lender would have been 

 

    	37

    	 

    

  

entitled to receive, except to the extent such
entitlement to receive a greater payment results from a change in law that occurs after the participant acquired the applicable
participation.

 

11.9         
Governing Law. This Agreement and the other Loan Documents have been negotiated and delivered to Agent and the Lenders in
the State of California, and shall have been accepted by Agent and the Lenders in the State of California. Payment to Agent and
the Lenders by Borrower of the Secured Obligations is due in the State of California. This Agreement and the other Loan Documents
(other than the Warrant) shall be governed by, and construed and enforced in accordance with, the laws of the State of California,
excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

 

11.10     
Consent to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of Section 11.11
is not applicable) arising in or under or related to this Agreement or any of the other Loan Documents may be brought in any state
or federal court located in the State of California. By execution and delivery of this Agreement, each party hereto generally and
unconditionally: (a) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (b) waives any
objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on
lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby
in connection with this Agreement or the other Loan Documents. Service of process on any party hereto in any action arising out
of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section
11.2, and shall be deemed effective and received as set forth in Section 11.2. Nothing herein shall affect the right to serve process
in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

 

		11.11	Mutual Waiver of Jury Trial / Judicial Reference.

 

(a)               
Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by
an experienced and expert Person and the parties wish applicable state and federal laws to apply (rather than arbitration rules),
the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER, AGENT AND THE LENDERS
SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY
CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY BORROWER AGAINST AGENT, THE LENDERS OR THEIR RESPECTIVE
ASSIGNEE OR BY AGENT, THE LENDERS OR THEIR RESPECTIVE ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including
Claims that involve Persons other than Agent, Borrower and the Lenders; Claims that arise out of or are in any way connected to
the relationship among Borrower, Agent and the Lenders; and any Claims for damages, breach of contract, tort, specific performance,
or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document.

 

(b)              
If the waiver of jury trial set forth in Section 11.11(a) is ineffective or unenforceable, the parties agree that all Claims
shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before
a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of the Santa Clara County,
California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery
applicable to such proceeding.

 

    	38

    	 

    

 

(c)               
In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in Section 11.10,
any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent
permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.

 

11.12     
Professional Fees. Borrower promises to pay Agent’s and the Lenders’ fees and expenses necessary to finalize
the loan documentation, including but not limited to reasonable and documented attorneys’ fees, UCC searches, filing costs,
and other miscellaneous expenses; provided that in no event shall such attorneys’ fees be in excess of $85,000. In addition,
Borrower promises to pay any and all reasonable and documented attorneys’ and other professionals’ fees and expenses
incurred by Agent and the Lenders after the Closing Date in connection with or related to: (a) the Loan; (b) the administration,
collection, or enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release,
or termination under the Loan Documents; (e) in conjunction with exercising rights and remedies after the occurrence and during
the continuance of an Event of Default; (f) the protection, preservation, audit, field exam, sale, lease, liquidation, or disposition
of Collateral or the exercise of remedies with respect to the Collateral; (g) any legal, litigation, administrative, arbitration,
or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (h)
any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related
to Borrower, the Collateral, the Loan Documents, including representing Agent or the Lenders in any adversary proceeding or contested
matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof.

 

11.13     
Confidentiality. Agent and the Lenders acknowledge that certain items of Collateral and information provided to Agent and
the Lenders by Borrower are confidential and proprietary information of Borrower, if and to the extent such information either
(x) is marked as confidential by Borrower at the time of disclosure, or (y) should reasonably be understood to be confidential
(the “Confidential Information”). Accordingly, Agent and the Lenders agree that any Confidential Information it may
obtain in the course of acquiring, administering, or perfecting Agent’s security interest in the Collateral shall not be
disclosed to any other Person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower,
except that Agent and the Lenders may disclose any such information: (a) to its Affiliates and its partners, investors, lenders,
directors, officers, employees, agents, advisors, counsel, accountants, counsel, representative and other professional advisors
if Agent or the Lenders in their sole discretion determines that any such party should have access to such information in connection
with such party’s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such
Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise
subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such
information is generally available to the public or to the extent such information becomes publicly available other than as a result
of a breach of this Section or becomes available to Agent or any Lender, or any of their respective Affiliates on a non-confidential
basis from a source other than the Borrower; (c) if required or appropriate in any report, statement or testimony submitted to
any Governmental Authority having or claiming to have jurisdiction over Agent or the Lenders and any rating agency; (d) if required
or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable
by Agent’s or the Lenders’ counsel; (e) to comply with any legal requirement or law applicable to Agent or the Lenders
or demanded by any Governmental Authority; (f) to the extent reasonably necessary in connection with the exercise of, or preparing
to exercise, or the enforcement of, or preparing to enforce, any 

 

    	39

    	 

    

  

right or remedy under any Loan Document (including
Agent’s sale, lease, or other disposition of Collateral after default), or any action or proceeding relating to any Loan
Document; (g) to any participant or assignee of Agent or the Lenders or any prospective participant or assignee, provided, that
such participant or assignee or prospective participant or assignee is subject to confidentiality restrictions that reasonably
protect against the disclosure of Confidential Information; (h) otherwise to the extent consisting of general portfolio information
that does not identify Borrower; or (i) otherwise with the prior consent of Borrower; provided, that any disclosure made in violation
of this Agreement shall not affect the obligations of Borrower or any of its Affiliates or any guarantor under this Agreement or
the other Loan Documents. Agent’s and the Lenders’ obligations under this Section 11.13 shall supersede all of their
respective obligations under the Non-Disclosure Agreement.

 

11.14     
Assignment of Rights. Borrower acknowledges and understands that Agent or the Lenders may, subject to Section 11.7, sell
and assign all or part of its interest hereunder and under the Loan Documents to any Person or entity (an “Assignee”).
After such assignment the term “Agent” or “Lender” as used in the Loan Documents shall mean and include
such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Agent and the Lenders hereunder with respect
to the interest so assigned; but with respect to any such interest not so transferred, Agent and the Lenders shall retain all rights,
powers and remedies hereby given. No such assignment by Agent or the Lenders shall relieve Borrower of any of its obligations hereunder.

 

11.15     
Revival of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and continue
to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent
or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower’s
assets, or if any payment or transfer of Collateral is recovered from Agent or the Lenders. The Loan Documents and the Secured
Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at
any time payment and performance of the Secured Obligations or any transfer of Collateral to Agent, or any part thereof is rescinded,
avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Agent, the Lenders
or by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,”
or otherwise, all as though such payment, performance, or transfer of Collateral had not been made. In the event that any payment,
or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured
Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent
of the full, final, and indefeasible payment to Agent or the Lenders in Cash.

 

11.16     
Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of
counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original,
but all of which counterparts shall constitute but one and the same instrument.

 

11.17     
No Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create
any third-party beneficiary rights or any other rights of any kind in any Person other than Agent, the Lenders and Borrower unless
specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal
and solely among Agent, the Lenders and the Borrower.

 

    	40

    	 

    

  

11.18     
Agency. Agent and each Lender hereby agree to the terms and conditions set forth on Addendum 3 attached hereto. Borrower
acknowledges and agrees to the terms and conditions set forth on Addendum 3 attached hereto.

 

11.19     
Publicity. None of the parties hereto nor any of its respective member businesses and Affiliates shall, without the other
parties’ prior written consent (which shall not be unreasonably withheld or delayed), publicize or use (a) the other party's
name (including a brief description of the relationship among the parties hereto), logo or hyperlink to such other parties’
web site, separately or together, in written and oral presentations, advertising, promotional and marketing materials, client lists,
public relations materials or on its web site (together, the "Publicity Materials"); (b) the names of officers of such
other parties in the Publicity Materials; and (c) such other parties’ name, trademarks, servicemarks in any news or press
release concerning such party; provided however, notwithstanding anything to the contrary herein, no such consent shall be required
(i) to the extent necessary to comply with the requests of any regulators, legal requirements or laws applicable to such party,
pursuant to any listing agreement with any national securities exchange (so long as such party provides prior notice to the other
party hereto to the extent reasonably practicable) and (ii) to comply with Section 11.13.

 

11.20     
Electronic Execution of Certain Other Documents. The words “execution,” “execute”, “signed,”
 “signature,” and words of like import in or related to any document to be signed in connection with this Agreement
and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents)
shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic
platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect,
validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be,
to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce
Act, the California Uniform Electronic Transaction Act, or any other similar state laws based on the Uniform Electronic Transactions
Act.

 

 

(SIGNATURES TO FOLLOW)

 

    	41

    	 

    

CONFIDENTIAL

 

 

IN WITNESS WHEREOF, Borrower, Agent and the
lenders have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.

 

 

	 	BORROWER:	 
	 	 	 
	 	CENTURY THERAPEUTICS, LLC	 
	 	 	 
	 	Signature:	/s/ Douglas Carr
	 	 	 
	 	Print Name:	Douglas Carr
	 	 	 
	 	Title:	Vice President Finance & Operations

 

 

Accepted in Palo Alto, California:

 

 

	 	AGENT:	 
	 	 	 
	 	 HERCULES CAPITAL, INC.	 
	 	 	 
	 	Signature:	/s/ Jennifer Choe
	 	 	 
	 	Print name:	 Jennifer Choe
	 	 	 
	 	Title:	Associate General Counsel
	 	 	 
	 	LENDERS:	 
	 	 	 
	 	HERCULES CAPITAL, INC.	 
	 	 	 
	 	Signature:	/s/ Jennifer Choe
	 	 	 
	 	Print name:	Jennifer Choe
	 	 	 
	 	Title:	Associate General Counsel

   

 

[Signature Page to Loan and Security Agreement]

  

 

    	 

    	 

    

  

Table of Addenda, Exhibits and Schedules

 

	Addendum 1:	Taxes; Increased
	Costs Addendum 2:	[Reserved]
	Addendum 3:	Agent and Lender Terms
	Exhibit A:	Advance Request

Attachment to Advance Request
	Exhibit B:	Name, Locations, and Other Information for Borrower
	Exhibit C:	Borrower’s Patents, Trademarks, Copyrights and Licenses
	Exhibit D:	Borrower’s Deposit Accounts and Investment Accounts
	Exhibit E:	Compliance Certificate
	Exhibit F:	Joinder Agreement
	Exhibit G:	[Reserved]
	Exhibit H:	ACH Debit Authorization Agreement
	Exhibit I:	[Reserved]
	Exhibit J-1:	Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)
	Exhibit J-2:	Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)
	Exhibit J-3:	Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)
	Exhibit J-4:	Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)
	Schedule 1.1	Commitments
	Schedule 1	Subsidiaries
	Schedule 1A	Existing Permitted Indebtedness
	Schedule 1B	Existing Permitted Investments
	Schedule 1C	Existing Permitted Liens
	Schedule 5.3	Consents, Etc.
	Schedule 5.8	Tax Matters
	Schedule 5.9	Intellectual Property Claims
	Schedule 5.10	Intellectual Property

 

    	2 

    	 

    

 

	Schedule 5.11	Borrower Products
	Schedule 5.14	Capitalization

 

    3

     

    

 

ADDENDUM 1 to LOAN
AND SECURITY AGREEMENT

TAXES; INCREASED COSTS

 

		1.	Defined Terms. For purposes of this Addendum 1:

 

		a.	“Connection Income Taxes” means Other Connection Taxes that are imposed on
or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.

 

		b.	“Excluded Taxes” means any of the following Taxes imposed on or with respect
to a Recipient or required to be withheld or deducted from a payment to a Recipient, (i) Taxes imposed on or measured by net income
(however denominated), franchise Taxes, and branch profits Taxes, in each case, (A) imposed as a result of such Recipient being
organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located
in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (B) that are Other Connection Taxes, (ii)
in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect
to an applicable interest in a Loan or Term Commitment pursuant to a law in effect on the date on which (A) such Lender acquires
such interest in the Loan or Term Commitment or (B) such Lender changes its lending office, except in each case to the extent that,
pursuant to Section 2 or Section 4 of this Addendum 1, amounts with respect to such Taxes were payable either to such Lender’s
assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office,
(iii) Taxes attributable to such Recipient’s failure to comply with Section 7 of this Addendum 1 and (iv) any withholding
Taxes imposed under FATCA.

 

		c.	“FATCA” means Sections 1471 through 1474 of the Code, as of the date of this
Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with),
any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1)
of the Code, and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement,
treaty or convention among Governmental Authorities and implementing such Sections of the Code.

 

		d.	“Foreign Lender” means a Lender that is not a U.S. Person.

 

		e.	“Indemnified Taxes” means (i) Taxes, other than Excluded Taxes, imposed on
or with respect to any payment made by or on account of any obligation of the Borrower under any Loan Document and (ii) to the
extent not otherwise described in clause (i), Other Taxes.

 

		f.	“Other Connection Taxes” means, with respect to any Recipient, Taxes imposed
as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections
arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under,
received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or
sold or assigned an interest in any Loan or Loan Document).

 

		g.	“Other Taxes” means all present or future stamp, court or documentary,
                                                                                                                                  intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery,
                                                                                                                                  performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with
                                                                                                                                  respect to, any Loan Document, 
	 	 	 

    	4 

    	 

    

  

			except any such Taxes that
                                                                               are Other Connection Taxes imposed with respect to an assignment.

 

		h.	“Recipient” means the Agent or any Lender, as applicable.

 

		i.	“Withholding Agent” means the Borrower and the Agent.

 

		2.	Payments Free of Taxes. Any and all payments by or on account of any obligation of the
Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable
law. If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction
or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled
to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority
in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the Borrower shall be increased
as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to
additional sums payable under this Section 2 or Section 4 of this Addendum 1) the applicable Recipient receives an amount equal
to the sum it would have received had no such deduction or withholding been made.

 

		3.	Payment of Other Taxes by Borrower. The Borrower shall timely pay to the relevant Governmental
Authority in accordance with applicable law, or at the option of the Agent timely reimburse it for the payment of, any Other Taxes.

 

		4.	Indemnification by Borrower. The Borrower shall indemnify each Recipient, within 10 days
after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable
to amounts payable under Section 2 of this Addendum 1 or this Section 4) payable or paid by such Recipient or required to be withheld
or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or
not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate
as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Agent), or by the Agent
on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.

 

		5.	Indemnification by the Lenders. Each Lender shall severally indemnify the Agent, within
10 days after demand therefor, for (a) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower
has not already indemnified the Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so),
(b) any Taxes attributable to such Lender’s failure to comply with the provisions of Section 11.8 of the Agreement relating
to the maintenance of a Participant Register and (c) any Excluded Taxes attributable to such Lender, in each case, that are payable
or paid by the Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto,
whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as
to the amount of such payment or liability delivered to any Lender by the Agent shall be conclusive absent manifest error. Each
Lender hereby authorizes the Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document
or otherwise payable by the Agent to the Lender from any other source against any amount due to the Agent under this Section 5.

 

		6.	Evidence of Payments. As soon as practicable after any payment of Taxes by the Borrower
to a Governmental Authority pursuant to the provisions of this Addendum 1, the Borrower shall deliver to 

    	5 

    	 

    

 

 

			the Agent the original or a certified copy of a receipt issued by such Governmental Authority
                                                                             evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably
                                                                             satisfactory to the Agent.

7. Status of Lenders

 

		a.	Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect
to payments made under any Loan Document shall deliver to the Borrower and the Agent, at the time or times reasonably requested
by the Borrower or the Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Agent
as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably
requested by the Borrower or the Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested
by the Borrower or the Agent as will enable the Borrower or the Agent to determine whether or not such Lender is subject to backup
withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the
completion, execution and submission of such documentation (other than such documentation set forth in Sections 7(b)(i), 7(b)(ii)
and 7(b)(iv) of this Addendum 1) shall not be required if in the Lender’s reasonable judgment such completion, execution
or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or
commercial position of such Lender.

 

		b.	Without limiting the generality of the foregoing, in the event that the Borrower is a U.S. Person,

 

		i.	any Lender that is a U.S. Person shall deliver to the Borrower and the Agent on or prior to
the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request
of the Borrower or the Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding
tax;

 

		ii.	any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower
and the Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender
becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent),
whichever of the following is applicable:

 

		A.	in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United
States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form
W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article
of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E
establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or
 “other income” article of such tax treaty;

 

		B.	executed copies of IRS Form W-8ECI;

 

		C.	in
the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x)
a certificate

    	6 

    	 

    

 

			substantially in the form of Exhibit J-1 to the effect that such Foreign Lender is not a
                                                                             “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the
                                                                             Borrower within the meaning of Section 871(h)(3)(B) of the Code, or a “controlled foreign corporation” related to
                                                                             the Borrower as described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and
                                                                             (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E; or

 

		D.	to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY,
accompanied by IRS Form W-8ECI, IRS Form W- 8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate substantially in the form
of Exhibit J-2 or Exhibit J-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided
that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the
portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit
J-4 on behalf of each such direct and indirect partner;

 

		iii.	any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower
and the Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender
becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent),
executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal
withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit
the Borrower or the Agent to determine the withholding or deduction required to be made; and

 

		iv.	if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding
Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those
contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Agent at
the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Agent such documentation
prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation
reasonably requested by the Borrower or the Agent as may be necessary for the Borrower and the Agent to comply with their obligations
under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the
amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause (iv), “FATCA” shall include
any amendments made to FATCA after the date of this Agreement.

 

		c.	Each Lender agrees that if any form or certification it previously delivered expires or becomes
obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Agent
in writing of its legal inability to do so.

 

		7.	Treatment of Certain Refunds. If any party determines, in its sole discretion
                                                                                                                        exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to the

    	7 

    	 

    

  

			provisions of this Addendum 1 (including by the payment of additional amounts pursuant to the
                                                                             provisions of this Addendum 1), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent
                                                                             of indemnity payments made under the provisions of this Addendum 1 with respect to the Taxes giving rise to such refund), net
                                                                             of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid
                                                                             by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such
                                                                             indemnified party, shall repay to such indemnified party the amount paid over pursuant to this Section 8 (plus any penalties,
                                                                             interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is
                                                                             required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this Section 8, in
                                                                             no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 8 the
                                                                             payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party
                                                                             would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or
                                                                             otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This
                                                                             Section 8 shall not be construed to require any indemnified party to make available its Tax returns (or any other information
                                                                             relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.

 

		8.	Increased Costs. If any change in applicable law shall subject any Recipient to any Taxes
(other than (A) Indemnified Taxes, (B) Taxes described in clauses (ii) through (iv) of the definition of Excluded Taxes and (C)
Connection Income Taxes) on its loans, loan principal, commitments, or other obligations, or its deposits, reserves, other liabilities
or capital attributable thereto, and the result shall be to increase the cost to such Recipient of making, converting to, continuing
or maintaining any Term Loan or of maintaining its obligation to make any such Loan, or to reduce the amount of any sum received
or receivable by such Recipient (whether of principal, interest or any other amount), then, upon the request of such Recipient,
the Borrower will pay to such Recipient such additional amount or amounts as will compensate such Recipient for such additional
costs incurred or reduction suffered.

 

		9.	Survival. Each party’s obligations under the provisions of this Addendum 1 shall
survive the resignation or replacement of the Agent or any assignment of rights by, or the replacement of, a Lender, the termination
of the Term Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.

    	8 

    	 

    

 

 

ADDENDUM 2 to LOAN AND
SECURITY AGREEMENT

 

[RESERVED]

 

    	 

    	 

    

 

 

ADDENDUM 3 to LOAN AND
SECURITY AGREEMENT

 

Agent
and Lender Terms

 

(a)               
Each Lender hereby irrevocably appoints Hercules Capital, Inc. to act on its behalf as the Agent hereunder and under the
other Loan Documents and authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to
the Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.

 

(b)              
Each Lender agrees to indemnify the Agent in its capacity as such (to the extent not reimbursed by Borrower and without
limiting the obligation of Borrower to do so), according to its respective Term Commitment percentages (based upon the total outstanding
Term Loan Commitments) in effect on the date on which indemnification is sought under this Addendum 3, from and against any and
all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind
whatsoever that may at any time be imposed on, incurred by or asserted against the Agent in any way relating to or arising out
of, this Agreement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions
contemplated hereby or thereby or any action taken or omitted by the Agent under or in connection with any of the foregoing; The
agreements in this Section shall survive the payment of the Loans and all other amounts payable hereunder.

 

(c)               
Agent in Its Individual Capacity. The Person serving as the Agent hereunder shall have the same rights and powers in its
capacity as a Lender as any other Lender and may exercise the same as though it were not the Agent and the term “Lender”
shall, unless otherwise expressly indicated or unless the context otherwise requires, include each such Person serving as Agent
hereunder in its individual capacity.

 

(d)              
Exculpatory Provisions. The Agent shall have no duties or obligations except those expressly set forth herein and in the
other Loan Documents. Without limiting the generality of the foregoing, the Agent shall not:

 

		(i)	be subject to any fiduciary or other implied duties, regardless of whether any default or any
Event of Default has occurred and is continuing;

 

		(ii)	have any duty to take any discretionary action or exercise any discretionary powers, except discretionary
rights and powers expressly contemplated hereby or by the other Loan Documents that the Agent is required to exercise as directed
in writing by the Lenders, provided that the Agent shall not be required to take any action that, in its opinion or the opinion
of its counsel, may expose the Agent to liability or that is contrary to any Loan Document or applicable law; and

 

		(iii)	except as expressly set forth herein and in the other Loan Documents, have any duty to disclose,
and the Agent shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates
that is communicated to or obtained by any Person serving as the Agent or any of its Affiliates in any capacity.

 

    	  

    	 

    

 

 

(e)               
The Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Lenders
or as the Agent shall believe in good faith shall be necessary, under the circumstances or (ii) in the absence of its own gross
negligence or willful misconduct.

 

(f)               
The Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation
made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other
document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of
the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default or Event of
Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other
agreement, instrument or document or (v) the satisfaction of any condition set forth in Section 4 or elsewhere herein, other than
to confirm receipt of items expressly required to be delivered to the Agent. Reliance by Agent. Agent may rely, and shall be fully
protected in acting, or refraining to act, upon, any resolution, statement, certificate, instrument, opinion, report, notice, request,
consent, order, bond or other paper or document that it has no reason to believe to be other than genuine and to have been signed
or presented by the proper party or parties or, in the case of cables, telecopies and telexes, to have been sent by the proper
party or parties. In the absence of its gross negligence or willful misconduct, Agent may conclusively rely, as to the truth of
the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to Agent and
conforming to the requirements of this Agreement or any of the other Loan Documents. Agent may consult with counsel, and any opinion
or legal advice of such counsel shall be full and complete authorization and protection in respect of any action taken, not taken
or suffered by Agent hereunder or under any Loan Documents in accordance therewith. Agent shall have the right at any time to seek
instructions concerning the administration of the Collateral from any court of competent jurisdiction. Agent shall not be under
any obligation to exercise any of the rights or powers granted to Agent by this Agreement and the other Loan Documents at the request
or direction of the Lenders unless Agent shall have been provided by the Lenders with adequate security and indemnity against the
costs, expenses and liabilities that may be incurred by it in compliance with such request or direction.

 

 

    	2 

    	 

    

 

 

EXHIBIT
A

ADVANCE REQUEST

 

	To:	Agent:	Date:	________,202__
	 	 	 	 
	 	Hercules Capital, Inc. (the “Agent”)
 400 Hamilton Avenue, Suite 310
 Palo Alto, CA 94301
 mail: legal@htgc.com

        Attn:
	 	 

 

 

CENTURY THERAPEUTICS, LLC, a Delaware limited
liability company (“Borrower”) hereby requests from Hercules Capital, Inc. (“Lender”) an Advance in the
amount of                Dollars ($                )
(the “Advance Amount”) on                                (the “Advance Date”) pursuant to the Loan and Security
Agreement among Borrower, Agent and the Lender (the “Agreement”). Capitalized words and other terms used but not otherwise
defined herein are used with the same meanings as defined in the Agreement.

 

Please:

 

		(a)	Issue a check payable to Borrower 	 	 

 

or

 

		(b)	Wire Funds to Borrower’s account 	 	 

 

	 	Bank:	 	 
	 	Address:	 	 
	 	 	 	 
	 	ABA Number:	 	 
	 	Account Number:	 	 
	 	Account Name:	 	 
	 	Contact Person:	 	 
	 	Phone Number To Verify Wire Info:	 	 
	 	Email address:	 	 
	 		 	 

 

  

Borrower represents that
the conditions precedent to the Advance set forth in the Agreement are satisfied and shall be satisfied upon the making of such
Advance, including but not limited to: (i) that no event that has had or could reasonably be expected to have a Material Adverse
Effect has occurred and is continuing; (ii) that the representations and warranties set forth in the Agreement and in the Warrant
are and shall be true and correct in all material respects (or, in the case of any representation and warranty qualified by materiality,
in all respects) on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent
such representations and warranties expressly relate to an earlier date (in which case such representations and warranties shall
be true and correct in all material respects as of such earlier date, or, in the case of any representation and warranty qualified
by materiality, in all respects as of such earlier date); (iii) that Borrower is in compliance with all material terms and provisions
set forth in each Loan Document on its part to be observed or performed; and (iv) that as of the Advance Date, no fact or condition
exists that could (or could, with the passage of time, the giving of 

 

    

     

    

 

notice, or both) constitute an Event of Default
under the Loan Documents. Borrower understands and acknowledges that Agent has the right to review the financial information supporting
this representation and, based upon such review in its sole discretion, the Lender may decline to fund the requested Advance.

 

Borrower hereby represents that
Borrower’s corporate status and locations have not changed since the date of the Agreement or, if the Attachment to this
Advance Request is completed, are as set forth in the Attachment to this Advance Request.

 

Borrower agrees to notify Agent
promptly before the funding of the Loan if any of the matters which have been represented above shall not be true and correct on
the Borrowing Date and if Agent has received no such notice before the Advance Date then the statements set forth above shall be
deemed to have been made and shall be deemed to be true and correct as of the Advance Date.

 

Executed as of [], 20[ ].

 

	BORROWER:
	CENTURY THERAPEUTICS, LLC
	 	 
	Signature:	 
	Title:	 
	Print Name:	 

 

    2

     

    

 

ATTACHMENT TO ADVANCE REQUEST

 

Dated:                                       

 

Borrower hereby represents and warrants to Agent
that Borrower’s current name and organizational status is as follows:

 

	Name:	CENTURY THERAPEUTICS, LLC
	Type of organization:	limited liability company
	State of organization:	Delaware
	Organization file number:	[                           ]

 

Borrower hereby represents and warrants to Agent
that the street addresses, cities, states and postal codes of its current locations are as follows:

 

[ ● ]

 

Borrower hereby represents and warrants to Agent
that the Advance Amount does not exceed the Maximum Term Loan Amount as follows:

 

		a.	Advance Amount: $                      

 

		b.	[Maximum Term Loan Amount: $                      ]

 

[c.Is clause a. less than or equal to clause b.?
Yes/Compliant                  No/Non-Compliant                ]

    	3 

    	 

    

 

EXHIBIT B

NAME,
LOCATIONS, AND OTHER INFORMATION FOR BORROWER

 

1.   
Borrower represents and warrants to Agent that Borrower’s current name and organizational status as of the Closing
Date is as follows:

 

	Name:	CENTURY THERAPEUTICS, LLC
	Type of organization:	limited liability company
	State of organization:	Delaware
	Organization file number:	7453663

 

 

2.   
Borrower represents and warrants to Agent that for five (5) years prior to the Closing Date, Borrower did not do business
under any other name or organization or form except the following:

 

Name: N/A

Used during dates of:N/A

Type of Organization:N/A

State of organization:N/A

Organization file Number: N/A

Borrower’s fiscal year ends on 12/31

Borrower’s federal employer tax identification
number is: 84-2040295

 

3.   
Borrower represents and warrants to Agent that its chief executive office is located at 3675 Market Street, Philadelphia,
PA 19104.

 

    	  

    	 

    

 

EXHIBIT C

BORROWER’S PATENTS,
TRADEMARKS, COPYRIGHTS AND LICENSES

 

Patents

 

None.

 

Registered Trademarks

 

None.

 

Registered Copyrights

 

None.

 

Material Agreements under which
Borrower licenses Intellectual Property from Third Parties (other than shrink-wrap software licenses)

 

License Agreement (differentiation) by and between the
Company (as assignee) and FUJIFILM Cellular Dynamics Inc., a Wisconsin corporation, signed September 18, 2018 (exclusive).

 

License Agreement (reprogramming) by and between the Company
(as assignee) and FUJIFILM Cellular Dynamics Inc., a Wisconsin corporation, effective September 18, 2018 (non-exclusive).

 

Master Collaboration Agreement by and between the Company
and FUJIFILM Cellular Dynamics Inc., a Wisconsin corporation, dated as of October 21, 2019.

 

Letter Agreement regarding WARF/CDI
License Agreement and CDI/Century Sublicense Agreement by and among the Company, FUJIFILM Cellular Dynamics Inc., a Wisconsin corporation
and Wisconsin Alumni Research Foundation dated as of July 2, 2019.

 

Sublicense Agreement by and between
the Company and iCell Inc., a Japanese corporation, effective as of March 20, 2020 (exclusive, excluding Japan).

 

Master Software and Service Agreement by and between
the Company, Century Therapeutics, Inc., a Delaware Corporation, and Labvantage Solutions, Inc., dated April 1, 2020.

    	  

    	 

    

 

EXHIBIT D

 

BORROWER’S DEPOSIT
ACCOUNTS AND INVESTMENT ACCOUNTS

 

 

 

	Bank Name	
        Account

        Number
	Branch Address	
        Borrower/

        Subsidiary
	
        Purpose of

        Account
	
        Avg.

        Balance

	
         

        Silicon Valley Bank
	
         

         

        [***]
	
         

        3003 Tasman Drive Santa Clara, CA 95054
	
        

        

        Borrower
	
        Primary operating account for all business
operations
	
        

        

        $2,000,000

	Silicon Valley Bank	
         

        [***]
	3003 Tasman Drive Santa Clara, CA 95054	
        

        Borrower
	
        Asset Management Account
	
        

        $42,000,000

	
        

        

        JP Morgan
	
        

        

        [***]
	 	
        

        

        Borrower
	
        Invest Excess cash, transferred to SVB
        Operating accountas needed
	
        

        

        $7,000,000

    	  

    	 

    

 

EXHIBIT E 

 

COMPLIANCE CERTIFICATE

 

Hercules Capital, Inc. (as “Agent”)

400 Hamilton Avenue, Suite 310 

Palo Alto, CA 94301

 

Reference is made to that certain
Loan and Security Agreement dated September 14, 2020 and the Loan Documents (as defined therein) entered into in connection with
such Loan and Security Agreement all as may be amended from time to time (hereinafter referred to collectively as the “Loan
Agreement”) by and among Hercules Capital, Inc. (the “Agent”), the several banks and other financial institutions
or entities from time to time party thereto (collectively, the “Lender”) and CENTURY THERAPEUTICS, LLC (the “Company”)
as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement.

 

The undersigned is an Officer
of the Company, knowledgeable of all Company financial matters, and is authorized to provide certification of information regarding
the Company; hereby certifies, in such capacity (and not in his or her personal capacity), that in accordance with the terms and
conditions of the Loan Agreement, to the knowledge of the undersigned, the Company is in compliance for the period ending                of
all covenants, conditions and terms and hereby reaffirms that, except as noted below, all representations and warranties contained
therein are true and correct on and as of the date of this Compliance Certificate with the same effect as though made on and as
of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect
in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties; provided
that the exceptions noted below shall not apply to an earlier date and shall not cure any default arising from any false or incorrect
misrepresentations and warranties previously made. Attached are the required documents supporting the above certification. The
undersigned further certifies that these are prepared in accordance with GAAP (except for the absence of footnotes with respect
to unaudited financial statement and subject to normal year-end adjustments) and are consistent from one period to the next except
as explained below.

 

	
         

        REPORTING REQUIREMENT
	
         

        REQUIRED
	CHECK IF ATTACHED
	Interim Financial Statements	Monthly within 30 days
	Interim Financial Statements	Quarterly within 45 days
	Audited Financial Statements	FYE within 180 days

 

 

ACCOUNTS OF BORROWER AND ITS SUBSIDIARIES AND AFFILIATES

 

The undersigned hereby also confirms the below disclosed
accounts represent all depository accounts and securities accounts presently open in the name of each Borrower or Borrower’s
Subsidiary/Affiliate, as applicable.

 

Each new account that has been opened since delivery
of the previous Compliance Certificate is designated below with a “*”.

 

	 	 	Depository AC #	Financial Institution	Account
    Type	Last
    Month  Ending	Purpose of Account

 

    	  

    	 

    

 

	 	 	 	 	(Depository / Securities)	Account Balance	 
	
        BORROWER

        Name/Address:
	 
	 	1	 	 	 	 	 
	2	 	 	 	 	 
	3	 	 	 	 	 
	4	 	 	 	 	 
	5	 	 	 	 	 
	6	 	 	 	 	 
	7	 	 	 	 	 
	 
	
        SUBSIDIARY / AFFILIATE

        Name/Address
	 
	 	1	 	 	 	 	 
	2	 	 	 	 	 
	3	 	 	 	 	 
	4	 	 	 	 	 
	5	 	 	 	 	 
	6	 	 	 	 	 
	7	 	 	 	 	 
	 

 

Name of Test                  Required Level                   Actual
Level                      In Compliance Y/N?

 

Minimum Cash*

 

[Effective if and only if Borrower has both: (a)
drawn the Tranche 2 Advance and (b) not achieved Performance Milestone II by September 30, 2021. See Section 7.20.]

 

		(a)	The amount of unrestricted Cash as of the date hereof: $                    

 

(b)   
The amount of the Borrower’s accounts payable not paid after the 90th day following the invoice date for such accounts
payable: $                   

    	  

    	 

    

 

(c) Clause (a) minus clause (b) is: $                                  

 

Is the amount reported in clause (c) equal to or greater
than $8,500,000?

 

     Yes;
     No

 

If No: not in compliance

 

* if the Tranche 2 Advance is not drawn or Borrower
has achieved Performance Milestone II by September 30, 2021, then there shall be no minimum cash requirement.

 

 

	Very Truly Yours,
	 
	CENTURY THERAPEUTICS, LLC
	 	 
	By:	 
	Name:	 
	Its:	 

 

 

    	  

    	 

    

 

EXHIBIT F

 

FORM OF JOINDER AGREEMENT

 

This Joinder Agreement (the
 “Joinder Agreement”) is made and dated as of [     ], 20[      ], and is entered into by and between          ., a          corporation
(“Subsidiary”), and HERCULES CAPITAL, INC., a Maryland corporation (as “Agent”).

 

RECITALS

 

A.   
Subsidiary’s Affiliate, CENTURY THERAPEUTICS, LLC (“Company”) [has entered/desires to enter] into that
certain Loan and Security Agreement dated September 14, 2020, with the several banks and other financial institutions or entities
from time to time party thereto as lender (collectively, the “Lenders”) and the Agent, as such agreement may be amended
(the “Loan Agreement”), together with the other agreements executed and delivered in connection therewith;

 

B.   
Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company’s execution of the
Loan Agreement and the other agreements executed and delivered in connection therewith;

 

AGREEMENT

 

NOW THEREFORE, Subsidiary and Agent agree as follows:

 

		1.	The recitals set forth above are incorporated into and made part of this
Joinder Agreement. Capitalized terms not defined herein shall have the meaning provided in the Loan Agreement.

 

		2.	By signing this Joinder Agreement, Subsidiary shall be bound by the terms
and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the Loan Agreement) under the Loan Agreement,
mutatis mutandis, provided however, that (a) with respect to (i) Section 5.1 of the Loan Agreement, Subsidiary represents that
it is an entity duly organized, legally existing and in good standing under the laws of [ ], (b) neither Agent nor the Lenders
shall have any duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other
Loan Documents, (c) that
if Subsidiary is covered by Company’s insurance, Subsidiary shall not be required to maintain separate insurance or
comply with the provisions of Sections 6.1 and 6.2 of the Loan Agreement, and (d) that
as long as Company satisfies the requirements of Section 7.1 of the Loan Agreement, Subsidiary shall not have to provide
Agent separate Financial Statements. To the extent that Agent or the Lenders has any duties, responsibilities or obligations
arising under or related to the Loan Agreement or the other Loan Documents, those duties, responsibilities or obligations
shall flow only to Company and not to Subsidiary or any other Person or entity. By way of example (and not an exclusive
list): (i) Agent’s providing notice to Company in accordance with the Loan Agreement or as otherwise agreed among
Company, Agent and the Lenders shall be deemed provided to Subsidiary; (ii) a Lender’s providing an Advance to Company
shall be deemed an Advance to Subsidiary; and (iii) Subsidiary shall have no right to request an Advance or make any other
demand on the Lenders.

		3.	Subsidiary agrees not to certificate its equity securities without Agent’s
prior written consent, which consent may be conditioned on the delivery of such equity securities to Agent in order to perfect
Agent’s security interest in such equity securities.

		4.	Subsidiary acknowledges that it benefits, both directly and indirectly,
from the Loan Agreement, and hereby waives, for itself and on behalf on any and all successors in interest (including without limitation
any assignee for the benefit of creditors, receiver, bankruptcy trustee or itself as debtor-in-possession under any bankruptcy
proceeding) to the fullest extent provided by law, any and all claims, rights or defenses to the enforcement of this Joinder Agreement
on the basis that (a) it failed to receive adequate consideration for the execution and delivery of this Joinder Agreement or (b)
its obligations under this Joinder Agreement are avoidable as a fraudulent conveyance.

 

    

     

    

 

	 	5	As security for the prompt, complete and indefeasible payment when due (whether on the payment dates or otherwise) of all the
Secured Obligations, Subsidiary grants to Agent a security interest in all of Subsidiary’s right, title, and interest
in and to the Collateral.

[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]

 

    	  

    	 

    

[SIGNATURE PAGE TO JOINDER AGREEMENT]

	 	SUBSIDIARY:	 
	 	 	 

 

	 	 
	 	By:	 	 
	 	Name:	 	 
	 	Title:	 	 
	 	 	 	 
	 	Address:	 	 
	 	 	 	 
	 	Telephone:	 	 
	 	email:	 	 

 

AGENT:

 

HERCULES CAPITAL, INC.

 

	 	By:	 	 
	 	Name:	                                	    
	 	Title:	 	 
	 	 	 	 
	 	Address:	 
	 	400 Hamilton Ave., Suite 310	 
	 	Palo Alto, CA 94301	 
	 	email: legal@htgc.com	 
	 	Telephone: 650-289-3060	 

 

    	  

    	 

    

 

EXHIBIT
G

 

[RESERVED]

 

    	  

    	 

    

 

EXHIBIT
I

 

ACH DEBIT AUTHORIZATION AGREEMENT

 

Hercules Capital, Inc.

400 Hamilton Avenue, Suite 310

Palo Alto, CA
94301

 

Re: Loan and Security Agreement dated September 14, 2020
(the “Agreement”) by and among CENTURY THERAPEUTICS, LLC (“Borrower”) and Hercules Capital, Inc., as agent
(“Company”) and the lenders party thereto (collectively, the “Lenders”)

 

In connection with the above
referenced Agreement, the Borrower hereby authorizes the Company to initiate debit entries for (i) the periodic payments due under
the Agreement and (ii) out-of-pocket legal fees and costs incurred by Agent or the Lenders pursuant to Section 11.12 of the Agreement
to the Borrower’s account indicated below. The Borrower authorizes the depository institution named below to debit to such
account.

 

 

 

[IF FILED PUBLICLY, ACCOUNT INFO REDACTED FOR SECURITY PURPOSES]

 

 

	DEPOSITORY NAME	BRANCH
	CITY	STATE AND ZIP CODE
	TRANSIT/ABA NUMBER	ACCOUNT NUMBER

 

 This authority will remain in full force and effect so long
as any amounts are due under the Agreement.

 

CENTURY THERAPEUTICS, LLC

(Borrower)

 

	By:	 
	Name:	 
	Date:	 
		 	 

 

 

    	  

    	 

    

 

EXHIBIT
I

 

[RESERVED]

  

    	  

    	 

    

 

EXHIBIT J-1

 

FORM OF U.S. TAX COMPLIANCE
CERTIFICATE

 

(For Foreign Lenders That Are Not Partnerships For
U.S. Federal Income Tax Purposes)

 

Reference is hereby made
to the Loan and Security Agreement dated as of September 14, 2020 (as amended, supplemented or otherwise modified from time to
time, the “Loan Agreement”) by and among CENTURY THERAPEUTICS, LLC, a Delaware limited liability company, and each
of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the “Borrower”), the
several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred
to as the “Lenders”), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and
collateral agent for itself and the Lenders (in such capacity, the “Agent”).

 

Pursuant to the provisions
of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the
Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii)
it is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a “ten percent shareholder”
of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a “controlled foreign corporation”
related to the Borrower as described in Section 881(c)(3)(C) of the Code.

 

The undersigned has furnished
the Agent and the Borrower with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing
this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall
promptly so inform the Borrower and the Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Agent
with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to
the undersigned, or in either of the two calendar years preceding such payments.

 

Unless otherwise defined
herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.

 

 

 

	Date:                , 20_	[NAME OF LENDER]
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 		 	 

 

    	  

    	 

    

 

 

EXHIBIT J-2

 

FORM OF U.S. TAX COMPLIANCE CERTIFICATE

 

(For Foreign Participants That
Are Not Partnerships For U.S. Federal Income Tax Purposes)

 

Reference is hereby made
to the Loan and Security Agreement dated as of September 14, 2020 (as amended, supplemented or otherwise modified from time to
time, the “Loan Agreement”) by and among CENTURY THERAPEUTICS, LLC, a Delaware limited liability company, and each
of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the “Borrower”), the
several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred
to as the “Lenders”), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and
collateral agent for itself and the Lenders (in such capacity, the “Agent”).

 

Pursuant to the provisions
of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the
participation in respect of which it is providing this certificate, (ii) it is not a “bank” within the meaning of Section
881(c)(3)(A) of the Code,

(iii) 
it is not a “ten percent shareholder” of the Borrower within the meaning of Section 871(h)(3)(B) of the Code
and (iv) it is not a “controlled foreign corporation” related to the Borrower as described in Section 881(c)(3)(C)
of the Code.

 

The undersigned has furnished
its participating Lender with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing
this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall
promptly so inform such Lender in writing, and (2) the undersigned shall have at all times furnished such Lender with a properly
completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned,
or in either of the two calendar years preceding such payments.

 

Unless otherwise defined herein,
terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.

 

 

 

	Date:                , 20_	[NAME OF PARTICIPANT]
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 		 	 

 

 

    	  

    	 

    

 

 

EXHIBIT J-3

 

FORM OF U.S. TAX COMPLIANCE CERTIFICATE

 

(For Foreign Participants That Are
Partnerships For U.S. Federal Income Tax Purposes)

 

Reference is hereby made
to the Loan and Security Agreement dated as of September 14, 2020 (as amended, supplemented or otherwise modified from time to
time, the “Loan Agreement”) by and among CENTURY THERAPEUTICS, LLC, a Delaware limited liability company, and each
of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the “Borrower”), the
several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred
to as the “Lenders”), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and
collateral agent for itself and the Lenders (in such capacity, the “Agent”).

 

Pursuant to the provisions
of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the participation
in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners
of such participation,

(iii) with respect to such participation, neither
the undersigned nor any of its direct or indirect partners/members is a “bank” extending credit pursuant to a loan
agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code,
(iv) none of its direct or indirect partners/members is a “ten percent shareholder” of the Borrower within the meaning
of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a “controlled foreign corporation”
related to the Borrower as described in Section 881(c)(3)(C) of the Code.

 

The undersigned has furnished
its participating Lender with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that
is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied
by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner’s/member’s beneficial owners that is claiming
the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided in
this certificate changes, the undersigned shall promptly so inform such Lender and (2) the undersigned shall have at all times
furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment
is to be made to the undersigned, or in either of the two calendar years preceding such payments.

 

Unless otherwise defined herein,
terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.

 

 

	Date:                , 20_	[NAME OF PARTICIPANT]
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 		 	 

 

    	  

    	 

    

 

 

EXHIBIT J-4

 

FORM OF U.S. TAX COMPLIANCE CERTIFICATE

 

(For Foreign Lenders That Are
Partnerships For U.S. Federal Income Tax Purposes)

 

Reference is hereby made
to the Loan and Security Agreement dated as of September 14, 2020 (as amended, supplemented or otherwise modified from time to
time, the “Loan Agreement”) by and among CENTURY THERAPEUTICS, LLC, a Delaware limited liability company, and each
of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the “Borrower”), the
several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred
to as the “Lenders”), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and
collateral agent for itself and the Lenders (in such capacity, the “Agent”).

 

Pursuant to the provisions
of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the Loan(s) (as well
as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) its direct or indirect
partners/members are the sole beneficial owners of such Loan(s) (as well as any promissory note(s) evidencing such Loan(s)),

(iii) with respect to the extension of credit pursuant
to this Loan Agreement or any other Loan Document, neither the undersigned nor any of its direct or indirect partners/members is
a “bank” extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business
within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a “ten percent
shareholder” of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect
partners/members is a “controlled foreign corporation” related to the Borrower as described in Section 881(c)(3)(C)
of the Code.

 

The undersigned has furnished the
Agent and the Borrower with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is
claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by
an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner’s/member’s beneficial owners that is claiming the
portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided in this
certificate changes, the undersigned shall promptly so inform the Borrower and the Agent, and (2) the undersigned shall have at
all times furnished the Borrower and the Agent with a properly completed and currently effective certificate in either the calendar
year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

 

Unless otherwise defined
herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.

 

 

	Date:                , 20_	[NAME OF LENDER]
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 		 	 

 

 

    	  

    	 

    

 

 

SCHEDULE 1.1

 

COMMITMENTS

 

Tranche 1 Advance

 

	LENDER	TERM COMMITMENT
	Hercules Capital, Inc.	$10,000,000

 

Tranche 2 Advance

 

	LENDER	TERM COMMITMENT
	Hercules Capital, Inc.	$10,000,000

 

Tranche 3 Advance

 

	LENDER	TERM COMMITMENT
	Hercules Capital, Inc.	$10,000,000*

*Subject to approval by Lender’s
investment committee in its sole discretion

 

 

Total Term Commitment

 

	LENDER	TERM COMMITMENT
	Hercules Capital, Inc.	$30,000,000*

    	  

    	 

    

 

 

Schedule 1 

Subsidiaries

 

 

 

Century Therapeutics Canada ULC

 

    	  

    	 

    

 

 

Schedule 1A

Existing Permitted Indebtedness

 

 

Promissory Note dated as of June 9, 2020, issued
by Century Therapeutics Canada ULC in favor of Empirica Therapeutics, Inc.

 

    	  

    	 

    

 

 

Schedule 1B

Existing Permitted Investments

 

None.

 

    	  

    	 

    

 

 

Schedule
1C 

Existing Permitted Liens

 

None.

 

    	  

    	 

    

 

 

Schedule 5.3 

Consents,
Etc.

 

None.

 

    	  

    	 

    

 

 

Schedule 5.8 

Tax
Matters

 

None.

 

    	  

    	 

    

 

 

Schedule
5.9 

Intellectual Property Claims

 

 

None.

 

    	  

    	 

    

 

 

Schedule
5.10

Intellectual Property

 

 

License Agreement (differentiation)
by and between the Borrower (as assignee) and FUJIFILM Cellular Dynamics Inc., a Wisconsin corporation, signed September 18, 2018
(exclusive).

 

License Agreement (reprogramming)
by and between the Borrower (as assignee) and FUJIFILM Cellular Dynamics Inc., a Wisconsin corporation, effective September 18,
2018 (non-exclusive).

 

Master Collaboration Agreement
by and between the Borrower and FUJIFILM Cellular Dynamics Inc., a Wisconsin corporation, dated as of October 21, 2019.

 

Letter Agreement regarding WARF/CDI
License Agreement and CDI/Century Sublicense Agreement by and among the Borrower, FUJIFILM Cellular Dynamics Inc., a Wisconsin
corporation and Wisconsin Alumni Research Foundation dated as of July 2, 2019.

 

    	  

    	 

    

 

 

Schedule
5.11 

Borrower Products

 

None.

 

    	  

    	 

    

 

 

Schedule 5.13 

Employee
Loans

 

None.

 

    	  

    	 

    

 

 

Schedule 5.14 Capitalization

 

Borrower

 

	Record Owners	 	Number of Units	 	Number of Unit Equivalents	 	Percentage Ownership
	Century Therapeutics, Inc.	 	 	67,226,891	 	 	 	—  	 	 	 	72	%
	Bayer Healthcare, LLC	 	 	26,143,790	 	 	 	—  	 	 	 	28	%
	Reserved	 	 	15,598,186	 	 	 	121,620	 	 	 	—  	 
	Total:	 	 	108,968,867	 	 	 	121,620	 	 	 	—  	 

 

 

Subsidiaries

 

	Subsidiary	Number of Shares	 	Percentage Ownership
	Century Therapeutics Canada ULC	 	 	100 shares of common stock	 	 	 	100%	

 

 

    	  

    	 

    

 

 

Schedule
7.22

Transactions with Affiliates

 

 

Shared Services Agreement, to be entered into between the
Borrower and Century Canada.Exhibit 10.27

 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is
not material and the registrant customarily and actually treats as private and confidential.

 

SUBLICENSE AGREEMENT

 

This Sublicense Agreement
(together with all exhibits and attachments hereto, this “Agreement”) is made and entered into by and between iCELL
Inc. (“Sublicensor”), a Japanese corporation having a principal place of business at Tokyo Twin Parks 25-26 FL (2505),
Higashi Shinbashi 1-10-2, Minato-ku, Tokyo 105-0021 Japan, and Century Therapeutics, LLC

(“Sublicensee”), a Delaware limited liability company having a principal place of business at 3675 Market St., Philadelphia,
PA 19104, effective as of March 20, 2020 (“Effective Date”).

 

WHEREAS, Sublicensor is party
to that Exclusive Licensing Agreement concluded on 08/01/2018 and as amended by that certain Amendment No. I to Exclusive Licensing Agreement
concluded as of even date herewith, between Sublicensor and The University of Tokyo

(“UTokyo”) and Todai TLO, Ltd., as may be further amended from time to time (“UTokyo License”), under
which Sublicensor was granted a license to certain patents, technology and technology information; and

 

WHEREAS, the Sublicensor desires
to grant to the Sublicensee a sublicense to such patents and technology, subject to the terms of this Agreement.

 

NOW, THEREFORE, and in consideration
of the mutual covenants and agreements

contained herein, the parties hereto agree as follows:

 

		1.	Definitions

 

		1.1.	“Field of Use” shall mean all fields of use.

 

		1.2.	“Initiation” shall mean the dosing of the first human subject participating in a clinical
trial.

 

		1.3.	“Inventors” shall mean the inventors of the Technology Information.

 

		1.4.	“Licensed Patents” shall mean the patents and applications listed in Exhibit A
                                                                hereto and any related patents and applications sharing the same priority date as those listed in this Agreement.

 

		1.5.	“Licensed Products” shall mean on a country-by-country basis, any product whose
                                                                manufacture, use, sale, offer for sale, or import which, but for the licenses granted herein, would infringe a Valid Claim of a
                                                                pending Licensed Patent, were such Licensed Patent to have issued, or a Valid Claim of an issued Licensed Patent in such country
                                                                in which such product is manufactured, used, sold, offered for sale, or imported.

 

		1.6.	“Technology Information” shall mean confidential, non-public technology
                                                                information, technical data, know-how and other information or materials controlled by Sublicensor during the term of this Agreement
                                                                that is necessary for the development and/or use of the Licensed Products which is provided to Sublicensee by or at the
                                                                direction of Sublicensor.

 

		1.7.	“Licensed Territories” shall mean France, Germany, Italy, Japan, Lichtenstein,
                                                                the Netherlands, Switzerland, the United States, the United Kingdom and any other countries where Valid Claims exist.

 

    

     

    

 

		1.8.	“Net Sales” shall mean the gross amount actually received by Sublicensee for sales
by Sublicensee, its affiliates and sublicensees of a Licensed Product to a third party, less the sum of the following actual
and customary deductions where applicable cash, trade or quantity discounts; sales, use, tariff, import/export duties or other
excise taxes when included in gross sales; transportation charges; and allowances or credits to customers because of rejections or
returns; retroactive price reductions; rebates; and government discounts.

 

		1.9.	“Valid Claim” shall mean, with respect to the patent rights within the Licensed Patents:
(a) a claim in an issued patent which has not (i) expired, (ii) been finally adjudicated or admitted as invalid or unenforceable, or (iii)
been abandoned; or (b) a claim in a pending application that has not been pending for more than eight (8) years and which is actively
being prosecuted.

 

		2.	Grant.

 

		2.1.	University of Tokyo License. A copy of the redacted UTokyo License is attached hereto as Schedule
                                                                1. Sublicensee acknowledges and agrees that the sublicense granted herein is subject to all restrictions, limitations, terms and
                                                                conditions of the UTokyo License applicable to a sublicensee, including without limitation, Articles 5, 7, 8, 9, 11 and 13 to 16 of
                                                                the UTokyo License,.

 

		2.2.	Sublicense to Licensed Patents. Sublicensor shall, and hereby does, grant to the Sublicensee an
exclusive, royalty bearing license under the Licensed Patents (collectively, the “Licensed Rights”), with the right
to grant sublicenses through multiple tiers, to research, develop, commercialize, make, have made, use, import, offer for sale, and sell
Licensed Products in the Licensed Territories during the term of this Agreement in the Field of Use provided, however, that in Japan such
license shall be non-exclusive.

 

		2.3.	Retained Rights. Any provision of this Agreement to the contrary notwithstanding, Sublicensor
                                                                reserves for itself and UTokyo an irrevocable, nonexclusive, royalty free, license to make and use the Technology Information for
                                                                their own internal educational and research activities practiced in non-profit research and as part of training and research
                                                                activities conducted by the Inventors and research collaborators (limited to those belonging to non-profit research institutions) of
                                                                laboratories that the Inventors may belong to in the future if they are no longer affiliated with UTokyo. Sublicensee shall include
                                                                such retained rights in any sublicenses it grants in accordance with this Agreement.

 

		2.4.	Technical Assistance. Sublicensor shall provide Sublicensee with access (by teleconference or in
person at Sublicensor’s facilities) as reasonably requested by Sublicensee to Sublicensor’s personnel involved in the research
and development of Licensed Products.

 

		2.5.	No Sublicense Without Compliance with UTokyo License. Sublicensee may grant sublicenses
                                                                through multiple tiers under this Agreement, with (i) prior written notice to Sublicensor, (ii) the inclusion in such sublicense of
                                                                all restrictions, limitations, terms and conditions of the UTokyo License applicable to a sublicensee, including without
                                                                limitation, Articles 5, 7, 8, 9, 11 and 13 to 16 of the UTokyo License, and (iii) UTokyo’s right to confer with Sublicensor if
                                                                UTokyo determines it has any concerns regarding such sublicensing.

 

    

     

    

 

		3.	Payments.

 

		3.1.	License Issue Fee. Sublicensee shall pay Sublicensor a one- time, non-creditable, and non-refundable
license issue fee (“License Issue Fee”) of US$100,000, due and payable within five (5) days of the Effective Date.

 

		3.2.	Earned Royalties. Sublicensee shall pay Sublicensor earned royalties (“Earned Royalties”)
on a country-by-country, Licensed Product-by-Licensed Product basis, beginning on the first commercial sale of the first Licensed Product
and continuing until the last-to-expire Valid Claim under the Licensed Patents claiming or covering such Licensed Product in such country,
in an amount equal to [***] of the Net Sales of such Licensed Product (“Earned Royalty Rate”) in the Field of Use by
Sublicensee and its affiliates and sublicensees.

 

		3.3.	Additional Earned Royalties. In addition to the Earned Royalties to be paid in accordance
                                                                with Section 3.2 above, Sublicensee shall pay Sublicensor additional sales milestone achievement payments (“Additional
                                                                Earned Royalties”) on a country-by-country basis until the last-to-expire Valid Claim under the Licensed Patents claiming
                                                                or covering Licensed Products, in the below amounts as additional one time payments based on achievement of Net Sales of Licensed
                                                                Products as follows:

 

3.3.1.       
If aggregate single calendar year Net Sales of all Licensed Products by Sublicensee and its affiliates and sublicensees in the
Licensed Territories exceed [***] for the first time, Sublicensee will make a one-time payment to Sublicensor of an Additional Earned
Royalty equal to [***] (solely for purposes of the UTokyo License, calculated at [***].

 

3.3.2.       
If aggregate single calendar year Net Sales of all Licensed Products by Sublicensee and its affiliates and sublicensees
in the Licensed Territories exceed [***] for the first time, Sublicensee will make a one-time payment to Sublicensor of an Additional
Earned Royalty equal to [***] (solely for purposes of the UTokyo License, calculated at [***]).

 

3.3.3.       
If aggregate single calendar year Net Sales of all Licensed Products by Sublicensee and its affiliates and sublicensees in the
Licensed Territories exceed [***] for the first time, Sublicensee will make a one-time payment to Sublicensor of an Additional Earned
Royalty equal to [***] (solely for purposes of the UTokyo License, calculated at [***]).

 

3.3.4.       
Each of the royalty payments set forth above in subsections 3.3.1, 3.3.2, 3.3.3 is payable only once and only upon the first achievement
of the applicable sales event for aggregate Net Sales of all Licensed Products as set forth above in subsections 3.3.1, 3.3.2, and 3.3.3
in the Licensed Territories, with no amounts due for subsequent or repeated achievements of such sales. For clarity, in no event shall
Sublicensee be required to pay Sublicensor more than an aggregate of Seventy Million U.S. Dollars ($70,000,000) as Additional Earned Royalties.

 

    

     

    

 

		3.4.	Late Payments. If any payment due hereunder that is not subject to a good faith dispute is not
paid when due for reasons attributable to Sublicensee and/or its affiliates and sublicensees such payment shall be subject to a late charge
from the date due until paid calculated at the rate of [***] per year.

 

		3.5.	Earned Royalties in Case of Challenge of the Licensed Patents. Should the Sublicensee challenge
the validity of any of the Licensed Patents:

 

 3.5.1.    

Provided that the outcome of such action be that any claim of a Patent Right challenged by Sublicensee is both valid and infringed by a Licensed Product, Sublicensee will pay Earned Royalties to the Sublicensor at the rate of 3x the then current Earned Royalty Rate of the Net Sales of all such Licensed Products sold;

 

3.5.2.    

Sublicensee will have no right to recoup expenses paid before or during the challenge; and

 

3.5.3.    

Any
dispute over the validity of the Sublicensor’s (or its licensor’s) Licensed Patents will be litigated in the courts located
in California. The parties agree not to challenge personal jurisdiction in that forum.

 

		4.	Development and Regulatory Approval Milestones and find other Obligations.

 

Sublicensee shall pay Sublicensor the applicable
milestone achievement payment set forth below within thirty (30) days after the first achievement of: each development and regulatory
approval milestone event described below by or on behalf of Sublicensee or its affiliates or sublicensees.

 

	Development and Regulatory Approval

 Milestone Event	Milestone Payment
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]

 

Each of the milestone payments
set forth above will be payable only once under this Agreement regardless of how many times the corresponding milestone event is achieved
by or on behalf of Sublicensee or its affiliates or sublicensees, with respect to one or more Licensed Products. For the avoidance of
doubt, in no event would Sublicensee be required to pay Sublicensor more than an aggregate of [***] in development and regulatory approval
milestone payments.

 

    

     

    

 

		5.	Records.

 

		5.1.	Maintenance of Records. During the term of this Agreement, Sublicensee shall maintain, and require
its affiliates and sublicensees to maintain, complete and accurate records of Licensed Products made, had made, used, offered for sale,
imported, or sold under this Agreement, and any amounts payable to Sublicensor in relation to such Licensed Products.

 

		5.2.	Annual Statement. Not later than March 1 of each calendar year, Sublicensee shall furnish to Sublicensor
a statement showing the Net Sales for each Licensed Product by Sublicensee and/or its affiliates and sublicensees during the immediate
preceding calendar year or portion thereof, and the Earned Royalties payable thereon calculated in such manner.

 

		5.3.	Retention of Records and Audit Rights. Sublicensee shall retain such records relating to a
                                                                given calendar year for at least five (5) years after the conclusion of that calendar year, during which time Sublicensor shall have
                                                                the right, at its expense, to cause an independent, certified public accountant to inspect and audit such records during normal
                                                                business hours and upon fourteen (14) business days
 prior written notice to Sublicensee for the sole purpose of verifying any
                                                                reports and payments delivered under this Agreement. Such accountant shall not disclose to Sublicensor any information other than
                                                                information relating to the accuracy of reports and payments delivered under this Agreement. The parties shall reconcile any
                                                                underpayment within [***] after such accountant delivers the results of the audit. Sublicensee shall also immediately pay to
                                                                Sublicensor a late payment charge calculated at an annual rate of [***] of the unpaid total for the number of days from the date
                                                                following the payment deadline to the date of payment. In the event that any audit performed under this Article 5 reveals an
                                                                underpayment in excess of [***] in any calendar year, Sublicensee shall bear the full cost of such audit. In the event that any
                                                                audit performed under this Article 5 reveals an overpayment in excess of [***] in any calendar year, Sublicensor shall bear the full
                                                                cost of such audit.

 

		6.	Instituting Infringement Actions.

 

		6.1.	Duty to Notify. Sublicensee shall promptly notify Sublicensor of any alleged infringement of the
Licensed Patents by a third party and of any available evidence of such infringement.

 

		6.2.	Sublicensee’s Right to Institute Infringement Suit. If the infringing activity has not
                                                                be abated or terminated without litigation within sixty (60) days following the effective date of the infringement notice,
                                                                Sublicensee shall have the right, but shall not be obligated, to institute suit for any infringement of the Licensed Patents, and
                                                                Sublicensor agrees to cooperate with Sublicensee in any such suit. Sublicensor further agrees to join as a party to any such suit if
                                                                Sublicensee reasonably deems the joinder to be necessary or appropriate. The total cost of any such infringement action (including,
                                                                any costs incurred by the Sublicensor arising out of such suit that Sublicensee requested Sublicensor join, including but not
                                                                limited to, any legal fees of counsel that the Sublicensor selects and retains to represent it in the suit) instituted by Sublicensee
shall be borne by Sublicensee, and Sublicensee shall retain any recovery or damages awarded in such action.

 

    

     

    

 

		6.3.	Sublicensor’s and UTokvo Right to Institute Suit. If, within one hundred and eighty
                                                                (180) days following the effective date of the infringement notice delivered pursuant to Section 6.1 above, the infringing activity
                                                                and misappropriation has not been abated and if Sublicensee has not brought suit addressing the infringement or misappropriation
                                                                pursuant to Section 6.2 above, Sublicensor or UTokyo under the UTokyo License, or both, shall have the right, but shall not be
                                                                obligated, to institute suit for any infringement of the Licensed Patents, and Sublicensee agrees to cooperate with Sublicensor, or
                                                                UTokyo, or both, in any such suit. Sublicensee further agrees to join as a party to any such suit if Sublicensor, or UTokyo, deems
                                                                the joinder to be necessary or appropriate. As between the Sublicensor and the Sublicensee, the total cost of any such infringement
                                                                action. (including, any costs incurred by the Sublicensee arising out of such suit, including but not limited to, any legal fees of
                                                                counsel that the Sublicensee selects and retains to represent it in the suit) instituted by Sublicensor and/or UTokyo, shall be
                                                                borne by Sublicensor and/or UTokyo, as applicable, and Sublicensor and/or UTokyo, as applicable, shall retain any recovery or
                                                                damages awarded in such action.

 

		7.	Warranties; Defending Infringement Actions; Indemnification; Covenants.

 

		7.1.	Warranties.

 

7.1.1.        Each
party represents and warrants to the other that as of the Effective Date it has full right, power and authority to enter into this
Agreement and to perform its respective obligations under this Agreement. Each party further represents and warrants that, as of the
Effective Date, the execution and delivery of this Agreement and the performance of such party’s obligations hereunder (a) do
not conflict with or violate any requirement of applicable laws and (b) do not conflict with, violate or breach or constitute a
default of, or require any consent under, any contractual obligations of such party, except such consents as have been obtained as
of the Effective Date.

 

7.1.2.       
Sublicensor represents and warrants to Sublicensee that it is the licensee of the Licensed Patents and has the right to grant the
Licensed Rights as set forth in this Agreement.

 

7.1.3.        Sublicensee
represents and warrants that any Licensed Products made or sold pursuant to this Agreement shall be made or sold in compliance with
all applicable federal and state law regulations, including but not limited to regulations of the Food and Drug Administration, the
Environmental Protection Agency and their state equivalents.

 

		7.2.	Defending Infringement Actions. If either party hereto or any affiliate, sublicensee or customer
thereof shall be charged with or sued for infringement of patent or other rights of a third party for performing any act contemplated
by this Agreement, such party shall promptly notify the other of all particulars of such charge or suit. Sublicensor and Sublicensee shall
consult and cooperate as appropriate in the disposition of each such charge and the defense of each such suit.

 

    

     

    

 

		7.3.	Indemnification.

 

		7.3.1.	Sublicensee will indemnify, hold harmless, and defend the Sublicensor, and its officers, directors,
                                                                  employees, and agents, (collectively, “Sublicensor Indemnitees”) against any and all claims, demands, actions,
                                                                  suits, losses, damages (including without limitation investigative costs, court costs, and attorneys’ fees), costs, fees, and
                                                                  expenses arising from third party claims resulting from or arising out of, (i) any material breach of this Agreement by
                                                                  Sublicensee, (ii) the gross negligence, intentional omission, or willful misconduct of Sublicensee, any permitted Sublicensee or
                                                                  affiliate or any employees, agents or representatives of Sublicensee, and (iii) death or injury to any person and damage to any
                                                                  property arising from the possession, manufacture, use or operation of Licensed Products produced or sold by Sublicensee or its
                                                                  affiliates, sublicensees or their customers in any manner whatsoever.

 

		7.3.2.	Sublicensor will indemnify, hold harmless, and defend the Sublicensee, and its officers, directors,
                                                                  employees, and agents, (collectively, “Sublicensee Indemnitees”) against any and all claims, demands, actions,
                                                                  suits, losses, damages (including without limitation investigative costs, court costs, and attorneys’ fees), costs, fees, and
                                                                  expenses arising from third party claims resulting from or arising out of, (i) any material breach of this Agreement by
                                                                  Sublicensor, and (ii) the gross negligence, intentional omission, or willful misconduct of Sublicensor or any employees, agents or
                                                                  representatives of Sublicensor.

 

		7.3.3.	The
party seeking indemnification under this Article 7 (an “Indemnified Party”) shall give prompt written notification
to the party from whom indemnification is sought (the “Indemnifying Party”) of any claim, suit, action or demand for
which indemnification is sought under this Agreement; provided, however, that no delay or failure on the part of an Indemnified Party
in so notifying the Indemnifying Party shall relieve the Indemnifying Party of any liability or obligation hereunder except to the extent
of any damage or liability caused by or arising out of such delay or failure. Within thirty (30) days after delivery of such notification,
the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such claim suit, action
or demand with counsel reasonably satisfactory to the Indemnified Party. If the Indemnifying Party does not assume control of such defense,
the Indemnified Party shall control such defense. The party not controlling such defense may participate therein with counsel of its
own choosing at its own expense; provided that, the Indemnified Party shall have the right to retain its own counsel, at the expense
of the Indemnifying Party, if representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate
because of actual or potential differences in the interests of such Indemnified Party and any other party represented by such counsel.
The Indemnified Party shall not agree to any settlement of such action, suit, proceeding or claim without the prior written consent of
the Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned. 

                                                                                

 

    

     

    

 

Insurance.
Sublicensee shall during the term of this Agreement maintain in full force and effect insurance policies and contractually assumed
liabilities in the amount of [***] and shall, upon reasonable request by Sublicensor no more than once each year, provide to
Sublicensor
 evidence of such policies. Sublicensee shall place appropriate product liability insurance prior to final regulatory
approval. With respect to one or more Licensed Products, and if requested by Sublicensor, such insurance policies shall name
Sublicensor as an additional insured.

 

		7.4.	Amendments of UTokyo License. Sublicensor will not amend any terms or conditions of the
                                                                UTokyo License in a manner that is reasonably likely to adversely affect Sublicensee’s rights hereunder, without written
                                                                approval of Sublicensee.

 

		8.	Limitations. EXCEPT FOR THE EXPRESS WARRANITIES IN SECTION 7, NEITHER PARTY MAKES, AND
                                                          EACH PARTY SPECIFICALLY DISCLAIMS, ANY WARRANTIES, EXPRESS OR IMPLIED, IN FACT OR BY OPERATION OF LAW, STATUTORY OR OTHERWISE,
                                                          INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, EFFICACY, AND NON-INFRINGEMENT. EXCEPT FOR (A)
                                                          DAMAGES FOR VIOLATIONS OF THE CONFIDENTIALITY OBLIGATIONS UNDER THIS AGREEMENT, (B) AMOUNTS FINALLY AWARDED FOR INDEMNIFICATION FOR
                                                          THIRD PARTY CLAIMS UNDER SECTION 7.3 HEREOF AND (C) DAMAGES FOR A PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, NEITHER
                                                          PARTY SHALL BE LIABLE TO THE OTHER PARTY OR TO ANY THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES
                                                          (INCLUDING LOST OR ANTICIPATED PROFITS RELATING TO THE SAME) ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH
                                                          CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED
                                                          OF THE POSSIBILITY OR LIKELIHOOD OF SAME.

 

		9.	Maintenance of Licensed Patents

 

		9.1.	Notifications. Notifications from government agencies or agents to Sublicensor concerning
                                                                procedures for the acquisition of rights for the Licensed Rights in the Licensed Territories and procedures for the maintenance of
                                                                the Licensed Patents shall be provided directly to Sublicensee from such government agency and Sublicensee shall have the first
                                                                right to control the preparation, filing, prosecution, extension and maintenance of patent rights within the Licensed Rights. To
                                                                the extent that government agencies or agents require Sublicensor to control such procedures, Sublicensor shall conduct said
                                                                procedures following consultation with, and the prior written consent of, Sublicensee.

 

		9.2.	Consultation. Sublicensee may at any time request consultation concerning the procedures for the
acquisition of rights for the Licensed Rights in the Licensed Territories. Sublicensor shall reasonably respond to these requests and
conduct these procedures after obtaining the consent of Sublicensee.

 

    

     

    

 

		9.3.	Expenses. During the Term, Sublicensee shall be responsible for the expenses (including
                                                                expenses for work requested of third parties including patent attorneys, attorneys and local agents outside of the United States as
                                                                well as translation expenses) required for the acquisition of rights for the Licensed Rights in the Licensed
Territories as well as the maintenance of patent rights within the Licensed Rights. If Sublicensor makes any such payment on behalf
of Sublicensee in advance, Sublicensor shall obtain the prior written consent of Sublicensee for the advance payment total and the
payment details and Sublicensee shall reimburse Sublicensor for such pre-approved expenses.

 

		9.4.	Patent Decisions. Regarding the Licensed Patents, if there has been a final rejection, trial
                                                                decision of refusal, a filing of opposition to the granting of a patent, a revocation decision, a request for a trial for patent
                                                                invalidation, a trial decision to invalidate a patent, or a revocation decision or a decision to invalidate a patent has been
                                                                confirmed or a request has been rejected, and circumstances impacting the Licensed Rights have arisen, Sublicensor shall immediately
                                                                notify Sublicensee of such facts.

 

		9.5.	No Abandonment. Sublicensor shall not abandon rights to any of the Licensed Patents without
                                                                the prior written consent of Sublicensee.

 

		9.6.	Revisions. Sublicensor shall obtain the prior written consent of Sublicensee if revising specifications
and drawings pertaining to the Licensed Patents.

 

		9.7.	Responsibility for Licensed Patents. Notwithstanding anything herein to the contrary,
                                                                Sublicensee will control and be responsible for preparing, filing, prosecuting, extending and maintaining patent rights within the
                                                                Licensed Patents in the Licensed Territories. Sublicensee will have the first right to defend such patent rights and enforce them
                                                                within the scope of this Agreement.

 

		10.	Term and Termination

 

		10.1.	Term. The term of this Agreement shall begin on the Effective Date and shall, unless earlier
                                                                 terminated as provided herein, continue until the later of March 31, 2027 or the last-to-expire Valid Claim claiming or covering a
                                                                 Licensed Product under this Agreement expires.

 

		10.2.	Sublicensor’s Right to Terminate. Under the following circumstances, in addition to any
                                                                 other rights of Sublicensor hereunder, Sublicensor may terminate this Agreement upon (30) day’s prior notice to Sublicensee
                                                                 without incurring any liability if:

 

10.2.1.    Sublicensee
has not made a payment of an amount not subject to a good faith dispute as provided for in this Agreement within sixty (60) days
after such payment becomes due, or if Sublicensee otherwise materially breaches any term of this Agreement and does not cure such
breach within thirty (30) days of receiving written notice thereof from Sublicensor.

 

		10.3.	Sublicensee’s Right to Terminate. In addition to any other rights of Sublicensee hereunder,
Sublicensee may terminate this Agreement:

 

10.3.1.   
Upon ninety (90) days prior written notice to Sublicensor without incurring any liability if any third party brings a claim against
Sublicensee over the Licensed Patents or the Technology Information, which the parties reasonably believe may render achievement of their
intent under this Agreement impossible, and such claim is not settled by Sublicensor within ninety (90) days;

 

    

     

    

 

10.3.2.   
Upon sixty (60) days prior written notice.

 

		10.4.	The parties agree that in the event of any termination of the UTokyo License with respect to any
                                                                 Licensed Rights sublicensed to Sublicensee hereunder, Sublicensee shall have any rights available under the UTokyo License to become
                                                                 a direct licensee of the licensor under such UTokyo License, and Sublicensor shall use its good faith efforts to assist Sublicensee
                                                                 in exercising such rights.

 

		11.	Confidentiality

 

		11.1.	Definition of Confidential Information. “Confidential Information” shall
                                                                 mean proprietary or confidential information provided or disclosed by or on behalf of one party (the “Disclosing
                                                                 Party”) to the other party (the “Recipient”) in connection with this Agreement, regardless of the
                                                                 medium that (a) is orally disclosed and indicated at the time of disclosure to be confidential or is confirmed in writing within
                                                                 fourteen (14) days of disclosure to be confidential, or (b) information not disclosed by verbal means that is marked as confidential
                                                                 or proprietary, or (c) that would otherwise be understood to be confidential or proprietary by a reasonable person familiar with the
                                                                 Disclosing Party’s industry due to the nature and context of the disclosure. Confidential Information that falls under any
                                                                 of the following items shall be excluded from the definition of Confidential Information: (i) information already in the
                                                                 possession of the Recipient at the time of provision or disclosure; (ii) information already publicly known at the time of provision
                                                                 or disclosure; (iii) information that became publicly known not due to the responsibility of the Recipient after provision or
                                                                 disclosure: (iv) information lawfully obtained from a third party with valid authority and no obligation of confidentiality to
                                                                 the Disclosing Party; (v) information independently developed by the Recipient without use of or reference to the Disclosing
                                                                 Party’s Confidential Information; or (vi) information with prior written consent to use or disclose from the Disclosing
                                                                 Party. The Recipient shall not use the Disclosing Party’s Confidential Information for any purpose other than to exercise
                                                                 its right or perform its obligations under this Agreement. The Recipient shall protect the confidentiality of the Disclosing
                                                                 Party’s Confidential Information using at least the same degree of care that it uses to protect its own confidential
                                                                 information of a similar nature, but in no event less than a reasonable degree of care. This Section 11 shall survive the
                                                                 expiration or termination of this Agreement for any reason for a period of five (5) years; provided, however, that this period
                                                                 can be lengthened or shortened upon written agreement between Sublicensor and Sublicensee. Nothing in this Agreement shall
                                                                 prohibit the Sublicensor from communicating certain terms of this Agreement to UTokyo to the extent necessary to comply with its
                                                                 obligations under the UTokyo License.

 

		11.2.	Third Party Disclosure. Neither party shall disclose the Disclosing Party’s Confidential
Information to any party except its own executives, employees, Inventors and agents (including patent attorneys, attorneys, certified
public accountants, tax accountants and consultants) who have a need to know such Confidential Information for the purpose of exercising
the Recipient’s rights or performing the Recipient’s obligations under this Agreement and who have entered into a written
confidentiality agreement with Recipient with provisions at least as restrictive as this
Article 11 or who are subject to fiduciary obligations of nondisclosure and non-use.

 

		11.3.	Required Disclosure. Either party lawfully ordered to disclose the Disclosing Party’s
                                                                 Confidential Information by a court or government agency, may disclose such information to said court or government agency on
                                                                 the condition that: (i) such party notifies the other party of the details of the disclosure beforehand if legally permitted; (ii)
                                                                 the disclosure is limited to what has been legally ordered; and (iii) when making the disclosure, confidential treatment is
                                                                 requested for such information.

 

		12.	Miscellaneous.

 

		12.1.	Assignment. This Agreement shall inure to the benefit of and be binding upon the parties
                                                                 hereto and their respective successors, and permitted assigns. This Agreement shall be personal to each of the Sublicensee and
                                                                 Sublicensor and assignable or otherwise transferable only with the prior written consent of the other party, provided, however, that
                                                                 either party may assign or transfer this Agreement without the other party’s consent to an affiliate or to a successor by way
                                                                 of merger, consolidation or sale of all or substantially all of the assets to which this Agreement relates.

 

		12.2.	Notices. All notices and payments required or contemplated hereunder by one party to the
                                                                 other shall be in writing and shall be deemed to have been duly made and given upon delivery if in person or by mailing if mailed by
                                                                 first-class mail, postage prepaid, and addressed as follows:

 

to Sublicensor: Tokyo Twin Parks 25-26
FL (2505),

 

    Higashi-Shinbashi
1-10-2, Minato-ku, Tokyo 105-0021 Japan,

 

to Sublicensee: Century Therapeutics,
LLC

 

    3675 Market St.

 

    Philadelphia, PA
19104

 

    Attn: Janelle R.
Anderson

 

Either party may change its address for
the purpose of this Agreement by notice in writing to the other party.

 

		12.3.	Entire Agreement: Amendment. This Agreement constitutes the entire agreement between the parties
respecting the subject matter hereof and shall not be modified, amended, or terminated except as provided herein or except by another
agreement in writing executed by an authorized representative of each of the parties hereto.

 

		12.4.	Applicable Law; Venue. This Agreement shall be governed, construed, and enforced in
                                                                 accordance with the laws of the State of California, United States of America, without application of its conflicts of laws
                                                                 principles. Each party irrevocably agrees, consents and submits to jurisdiction and venue in the federal and state courts in San
                                                                 Francisco, California, with respect to any dispute arising out of or relating in any way to this Agreement.

 

    

     

    

 

		12.5.	No Partnership. Nothing in this Agreement shall be construed as creating or constituting a joint
venture, partnership, employment relationship, or franchise between Sublicensor and Sublicensee.

 

		12.6.	Severability. All rights and restrictions contained in this Agreement may be exercised and
                                                                 shall be applicable and binding only to the extent that they do not violate any applicable laws and are intended to be limited to
                                                                 the extent necessary so that they will not render this Agreement illegal, invalid or unenforceable. If any term of this
                                                                 Agreement shall be held to be illegal, invalid, or unenforceable, it is the intention of the parties that the remaining parts
                                                                 hereof shall constitute their Agreement with respect to the subject matter hereof and all of its remaining terms shall be in full
                                                                 force and effect.

 

		12.7.	Waiver. Waiver by either party of any term or provision of this Agreement shall not
                                                                 constitute a continuing waiver thereof nor of any further or additional rights such party may hold under this Agreement.

 

		12.8.	Hearings. Article and Section headings have been inserted herein for convenience of reference
                                                                 only and shall in no way modify or restrict any of the terms or provisions of this Agreement.

 

		12.9.	Survival. The provisions of Articles 1, 5, 7.3, 8, 10.4, 11, and 12 shall survive and remain
                                                                 valid even after the expiration or termination of the Agreement (regardless of the reason for termination). Clauses with a surviving
                                                                 period of validity clearly stated in the Agreement shall remain valid for said period even after the expiration or termination
                                                                 of the Agreement (regardless of the reason for termination).

 

		12.10.	Export. Sublicensee acknowledges that the Licensed Products may be subject to United States
                                                                  laws and regulations controlling the export of technical data, biological materials, chemical compositions, computer software,
                                                                  laboratory prototypes and other commodities and that Sublicensee shall be responsible for compliance with applicable United States
                                                                  export laws and regulations.

 

		12.11.	Counterparts. This Agreement may be executed in counterparts and by facsimile or electronic means
each of which shall be an original and together one and the same instrument.

 

[Signatures Appear on Following Page]

 

    

     

    

 

IN WITNESS WHEREOF, the parties
hereto have affixed their signatures as of the Effective Date.

 

SUBLICENSOR

 

iCELL Inc.

 

	By:	       /s/ Genjiro Miwa	 
	 	 
	Name: Genjiro Miwa	 
	 	 
	Title: Representative Director	 

 

SUBLICENSEE

 

Century Therapeutics, LLC

 

	By:	        /s/ Osvaldo Flores	 
	 	 
	Name: Osvaldo (Lalo) Flores, PhD	 
	 	 
	Title: Chief Executive Officer	 

 

    

     

    

 

Exhibit A

 

TABLE OF PATENTS LICENSED FROM THE UNIVERSITY OF
TOKYO

 

[***]

 

    

     

    

 

Schedule 1

 

UTOKYO LICENSE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]